Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Chronic Heart Failure

  Free Subscription


Articles published in Eur J Heart Fail

Retrieve available abstracts of 808 articles:
HTML format



Single Articles


    March 2023
  1. FUDIM M, Parikh K, Ganesh A, Molinger J, et al
    Splanchnic Nerve Block with Botulinum Toxin for Therapy of Chronic Heart Failure - Mechanism of Action (SPONGE-HF).
    Eur J Heart Fail. 2023 Mar 16. doi: 10.1002/ejhf.2829.
    PubMed    


  2. ZANNAD F, Alikhaani J, Alikhaani S, Butler J, et al
    PATIENT REPORTED OUTCOME MEASURES AND PATIENT ENGAGEMENT IN HEART FAILURE CLINICAL TRIALS: MULTI-STAKEHOLDER PERSPECTIVES.
    Eur J Heart Fail. 2023 Mar 16. doi: 10.1002/ejhf.2828.
    PubMed     Abstract available


  3. DOBBIN SJH, Shen L, Petrie MC, Packer M, et al
    Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials.
    Eur J Heart Fail. 2023 Mar 15. doi: 10.1002/ejhf.2818.
    PubMed     Abstract available


  4. PANDEY AK, Dhingra NK, Pandey A, Puar P, et al
    Efficacy of sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors for heart failure in black patients: a systematic review and meta-analysis of randomized controlled trials.
    Eur J Heart Fail. 2023 Mar 15. doi: 10.1002/ejhf.2825.
    PubMed    


  5. SAITO Y, Obokata M, Harada T, Kagami K, et al
    Disproportionate exercise-induced pulmonary hypertension in relation to cardiac output in heart failure with preserved ejection fraction: a non-invasive echocardiographic study.
    Eur J Heart Fail. 2023 Mar 13. doi: 10.1002/ejhf.2821.
    PubMed     Abstract available


  6. PAGNESI M, Adamo M, Ter Maaten JM, Beldhuis IE, et al
    Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX-AHF-2 trial.
    Eur J Heart Fail. 2023 Mar 13. doi: 10.1002/ejhf.2820.
    PubMed     Abstract available


    February 2023
  7. BLUMER V, Truby LK, Zieroth S
    Sex Differences in Heart Failure: The Evolving Use of Biomarkers.
    Eur J Heart Fail. 2023 Feb 28. doi: 10.1002/ejhf.2817.
    PubMed    


  8. PACKER M
    Dosing of Iron Supplementation for Iron-Deficient Patients With Heart Failure: Should We Prefer More Intensive or Less Intensive Repletion Targets?
    Eur J Heart Fail. 2023 Feb 28. doi: 10.1002/ejhf.2816.
    PubMed    


  9. GUSTAFSSON F, Damman K, Nalbantgil S, Van Laake LW, et al
    Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2023 Feb 27. doi: 10.1002/ejhf.2814.
    PubMed     Abstract available


  10. GARD EK, Beale AL, Telles F, Silvestry FE, et al
    Left atrial enlargement is associated with pulmonary vascular disease in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2023 Feb 27. doi: 10.1002/ejhf.2805.
    PubMed     Abstract available


  11. CHIONCEL O, Antohi L, Mebazaa A
    Heart Failure and Non-cardiac Surgery: "A Call To Action" for Multidisciplinary Care Supporting Surgeons and Anesthesiologists.
    Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2813.
    PubMed    


  12. FENG KY, Ambrosy AP, Zhou Z, Li D, et al
    Association Between Serum Albumin and Outcomes in Heart Failure and Secondary Mitral Regurgitation: The COAPT Trial.
    Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2809.
    PubMed     Abstract available


  13. GRAHAM FJ, Pellicori P, Kalra PR, Ford I, et al
    Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis.
    Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2810.
    PubMed     Abstract available


  14. SANZ-RUIZ R, Perin EC, Fernandez-Aviles F
    Cell Therapy for Heart Failure: Lessons Learned from SCIENCE.
    Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2807.
    PubMed    


  15. MARCHANDOT B, Trimaille A, Morel O
    Letter regarding the article "Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes".
    Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2812.
    PubMed    


  16. JANKOWSKA EA, Liu PP, Cowie MR, Groenhart M, et al
    Personalised care of patients with heart failure - are we ready for a REWOLUTION? Insights from two international surveys on healthcare professionals' needs and patients' perceptions.
    Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2798.
    PubMed     Abstract available



  17. Correction to: "A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry" and articles listed below.
    Eur J Heart Fail. 2023 Feb 17. doi: 10.1002/ejhf.2789.
    PubMed    


  18. MICHOU E, Wussler D, Mueller C
    Reply to the Letter to the Editor regarding the article "Quantifying inflammation using Interleukin-6 for improved phenotyping and risk stratification in acute heart failure".
    Eur J Heart Fail. 2023 Feb 15. doi: 10.1002/ejhf.2802.
    PubMed    


  19. ABBASI MA, Borlaug BA
    Pulmonary vascular disease in heart failure with preserved ejection fraction: the evidence grows.
    Eur J Heart Fail. 2023 Feb 15. doi: 10.1002/ejhf.2800.
    PubMed    


  20. LONCAR G, Garfias-Veitl T, Valentova M, Vatic M, et al
    Bone status in men with heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure.
    Eur J Heart Fail. 2023 Feb 13. doi: 10.1002/ejhf.2794.
    PubMed     Abstract available


  21. CAPPELLETTO C, Stolfo D, Orsini N, Benson L, et al
    Use of and Association between Heart Failure Pharmacological Treatments and Outcomes in Obese vs. non-Obese Patients with Heart Failure with Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2023 Feb 13. doi: 10.1002/ejhf.2795.
    PubMed     Abstract available


  22. KALOGEROPOULOS AP, Lewis GD
    Benefits of Intravenous Iron Supplementation in Patients with Heart Failure: Mounting Evidence and Open Questions.
    Eur J Heart Fail. 2023 Feb 1. doi: 10.1002/ejhf.2787.
    PubMed    


  23. PATEL L, Keshvani N, Pandey A
    Are post-influenza vaccine reactions truly 'adverse'?
    Eur J Heart Fail. 2023;25:311-312.
    PubMed    


  24. DOMINGUEZ F, Cabrera E
    Mavacamten in obstructive hypertrophic cardiomyopathy - Are beta-blockers blocking part of its shine?
    Eur J Heart Fail. 2023;25:271-273.
    PubMed    


  25. LIM HS, Yim IHW
    De novo aortic regurgitation related to left ventricular assist device therapy: the difficult questions in need of new perspectives.
    Eur J Heart Fail. 2023;25:295-298.
    PubMed    


  26. OMOTE K, Verbrugge FH, Sorimachi H, Omar M, et al
    Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea.
    Eur J Heart Fail. 2023;25:185-196.
    PubMed     Abstract available


  27. URIEL N, Milano C, Agarwal R, Lee S, et al
    Incidence and clinical correlates of de-novo aortic regurgitation with a fully magnetically levitated left ventricular assist device: a MOMENTUM 3 trial portfolio analysis.
    Eur J Heart Fail. 2023;25:286-294.
    PubMed     Abstract available


  28. WHEELER MT, Jacoby D, Elliott PM, Saberi S, et al
    Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
    Eur J Heart Fail. 2023;25:260-270.
    PubMed     Abstract available


  29. PEIKERT A, Claggett BL, Kim K, Udell JA, et al
    Association of post-vaccination adverse reactions after influenza vaccine with mortality and cardiopulmonary outcomes in patients with high-risk cardiovascular disease: the INVESTED trial.
    Eur J Heart Fail. 2023;25:299-310.
    PubMed     Abstract available


  30. LEVI N, Moravsky G, Weitsman T, Amsalem I, et al
    A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons.
    Eur J Heart Fail. 2023;25:313-318.
    PubMed     Abstract available


    January 2023
  31. MCEWAN P, Harrison C, Binnie R, Lewis RD, et al
    Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalisation: A European multinational economic evaluation.
    Eur J Heart Fail. 2023 Jan 31. doi: 10.1002/ejhf.2788.
    PubMed     Abstract available


  32. WANG S, Sun J, Wang L
    Interleukin-6 in acute heart failure: it does work, but how much? Letter regarding the article 'Quantifying inflammation using Interleukin-6 for improved phenotyping and risk stratification in acute heart failure'.
    Eur J Heart Fail. 2023 Jan 25. doi: 10.1002/ejhf.2785.
    PubMed    


  33. FUCHS ANDERSEN C, Glenthoj A, Jensen J
    Letter regarding the editorial "Little at a time: trying to understand the battery of benefits of SGLT2 inhibitors in heart failure".
    Eur J Heart Fail. 2023 Jan 24. doi: 10.1002/ejhf.2782.
    PubMed    


  34. WEENING EH, Al-Mubarak AA, Damman K, Voors AA, et al
    Trace element equilibrium in acute heart failure and the effect of empagliflozin.
    Eur J Heart Fail. 2023 Jan 24. doi: 10.1002/ejhf.2779.
    PubMed    


  35. LECLERCQ C, Burri H
    His bundle pacing for correcting atrioventricular dyssynchrony in heart failure: HYPE or HOPE?
    Eur J Heart Fail. 2023 Jan 17. doi: 10.1002/ejhf.2775.
    PubMed    


  36. GUALANDRO DM, Puelacher C, Chew MS, Andersson H, et al
    Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes.
    Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2773.
    PubMed     Abstract available


  37. SAVARESE G, Lindenfeld J, Stolfo D, Adams K, et al
    Use of Patient-Reported Outcomes in Heart Failure: From Clinical Trials to Routine Practice.
    Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2778.
    PubMed     Abstract available


  38. MILLER RJ, Chew DS, Qin L, Fine NM, et al
    Cost-effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure.
    Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2777.
    PubMed     Abstract available


  39. MASTORIS I, Campain J, Lewis GD
    Invasive Exercise Hemodynamics: An Oracle in Heart Failure with Preserved Ejection Fraction Diagnosis and Prognostication.
    Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2774.
    PubMed    


  40. QAYYUM AA, van Klarenbosch B, Frljak S, Cerar A, et al
    Effect of allogeneic adipose tissue derived mesenchymal stromal cell treatment in chronic ischemic heart failure with reduced ejection fraction - The SCIENCE Trial.
    Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2772.
    PubMed     Abstract available


  41. ORBAN M, Rottbauer W, Williams M, Mahoney P, et al
    Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation with 3(rd) Generation Devices in Heart Failure Patients-Results from the Global EXPAND Post-Market Study.
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2770.
    PubMed     Abstract available


  42. AIMO A, Bayes-Genis A
    Biomarkers of inflammation in heart failure: from risk prediction to possible treatment targets.
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2771.
    PubMed    


  43. GRASSI G
    HEART FAILURE RELATED CENTRAL SYMPATHETIC ACTIVATION: DEBUNKING THE "HOLY GRAIL" ?
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2764.
    PubMed    


  44. MICHOU E, Wussler D, Belkin M, Simmen C, et al
    Quantifying inflammation using Interleukin-6 for improved phenotyping and risk stratification in acute heart failure.
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2767.
    PubMed     Abstract available


  45. VON HAEHLING S, Sato R, Butler J, Anker SD, et al
    Little at a time: trying to understand the battery of benefits of SGLT2 inhibitors in heart failure.
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2766.
    PubMed    


  46. VARSHNEY AS, Berg DD, Zhou G, Sinnenberg L, et al
    Bridging Strategies and Cardiac Replacement Outcomes in Patients with Acute Decompensated Heart Failure-Related Cardiogenic Shock.
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2762.
    PubMed     Abstract available


  47. DOCHERTY KF, McMurray JJV, Claggett BL, Miao ZM, et al
    Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial.
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2763.
    PubMed     Abstract available


  48. VAN DER HOEF CCS, Boorsma EM, Emmens JE, van Essen BJ, et al
    Biomarker signature and pathophysiological pathways in chronic heart failure patients with metabolic syndrome.
    Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2760.
    PubMed     Abstract available


  49. TOMASONI D, Adamo M, Metra M
    January 2023 at a glance: focus on acute heart failure and medical therapy.
    Eur J Heart Fail. 2023;25:1-3.
    PubMed    


  50. CARAVITA S, Baratto C
    Understanding mechanisms of Fontan failure: exercise haemodynamics to unmask diastolic dysfunction, again!
    Eur J Heart Fail. 2023;25:26-29.
    PubMed    


  51. CODINA P, Lupon J, Subirana I, Zamora E, et al
    Barcelona Bio-HF calculator version 3.0: recalibration and incorporation of sodium-glucose cotransporter 2 inhibitor treatment.
    Eur J Heart Fail. 2023;25:131-132.
    PubMed    


  52. BERTERO E, Maack C
    The attack of the clones to the cardiovascular system.
    Eur J Heart Fail. 2023;25:14-16.
    PubMed    


  53. YU Y, Niu H, Hua W
    Letter regarding the article 'Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure'.
    Eur J Heart Fail. 2023;25:133.
    PubMed    


    December 2022
  54. BORIANI G, Imberti JF, Vitolo M
    The burden of atrial fibrillation in patients with preserved or mildly reduced heart failure: a call to action for detecting atrial fibrillation and improving outcome.
    Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2755.
    PubMed    


  55. KALOGEROPOULOS AP, Jacobs M
    Improve Heart Function to Improve Heart Failure Outcomes: The Disease-Modifying Effects of Spironolactone.
    Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2757.
    PubMed    


  56. CARBONE S, daSilva-deAbreu A, Lavie CJ
    Weighing in on Weight Loss in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2753.
    PubMed    


  57. COTTER G, Davison B, Cohen-Solal A, Freund Y, et al
    Targeting the "vulnerable" period - first 3 - 6 months after an acute heart failure admission - the light gets brighter.
    Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2754.
    PubMed    


  58. HUNGERFORD SL, Dahle G, Duncan A, Hayward CS, et al
    Peri-procedural management of transcatheter mitral valve replacement in patients with heart failure.
    Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2758.
    PubMed     Abstract available


  59. INCIARDI R, Pellicori P, Chandra A
    Identification and Quantification of Congestion in Heart Failure: a Work in Progress.
    Eur J Heart Fail. 2022 Dec 4. doi: 10.1002/ejhf.2751.
    PubMed    


  60. BADROV MB, Keir DA, Tomlinson G, Notarius CF, et al
    Normal and excessive muscle sympathetic nerve activity in heart failure: implications for future trials of therapeutic autonomic modulation.
    Eur J Heart Fail. 2022 Dec 2. doi: 10.1002/ejhf.2749.
    PubMed     Abstract available


  61. TOMASONI D, Adamo M, Metra M
    December 2022 at a glance: heart failure with preserved ejection fraction, sodium-glucose cotransporter 2 inhibitors and cardiac amyloidosis.
    Eur J Heart Fail. 2022;24:2209-2211.
    PubMed    


  62. PATEL RK, Ioannou A, Razvi Y, Chacko L, et al
    Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis.
    Eur J Heart Fail. 2022;24:2355-2363.
    PubMed     Abstract available


  63. CERLINSKAITE-BAJORE K, Mebazaa A, Celutkiene J
    Guideline-directed medical therapy improves not only left but also right heart function.
    Eur J Heart Fail. 2022;24:2235-2237.
    PubMed    


  64. CHANDRA A, Polanczyk CA, Claggett BL, Vaduganathan M, et al
    Health-related quality of life outcomes in PARAGON-HF.
    Eur J Heart Fail. 2022;24:2264-2274.
    PubMed     Abstract available


  65. DOMINGUEZ-RODRIGUEZ A, Hernandez-Vaquero D, Miro O
    Reply to 'Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?'.
    Eur J Heart Fail. 2022;24:2393-2394.
    PubMed    


  66. NETO GONCALVES T, Margarida Andrade M
    Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice? Letter regarding the article 'Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled tri
    Eur J Heart Fail. 2022;24:2392-2393.
    PubMed    


  67. NICKLAS JM, Perry D
    Non-intuitive findings from the MEMS-HF haemodynamic substudy.
    Eur J Heart Fail. 2022;24:2331-2332.
    PubMed    


  68. NITSCHE C
    How prevalent is cardiac amyloidosis and which patients should be screened?
    Eur J Heart Fail. 2022;24:2352-2354.
    PubMed    


  69. RAPEZZI C, Emdin M, Aimo A
    Unravelling the role of sex in the pathophysiology, phenotypic expression and diagnosis of cardiac amyloidosis.
    Eur J Heart Fail. 2022;24:2364-2366.
    PubMed     Abstract available


  70. MAESTRO-BENEDICTO A, Vela P, de Frutos F, Mora N, et al
    Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Eur J Heart Fail. 2022;24:2367-2373.
    PubMed     Abstract available


  71. AIMO A, Merlo M, Porcari A, Georgiopoulos G, et al
    Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.
    Eur J Heart Fail. 2022;24:2342-2351.
    PubMed     Abstract available


    November 2022
  72. SINHA A, Patel RB
    Loop diuretic management after sacubitril/valsartan initiation in heart failure with preserved ejection fraction: deceptively simple or more than meets the eye?
    Eur J Heart Fail. 2022 Nov 29. doi: 10.1002/ejhf.2750.
    PubMed    


  73. LIN DS, Lin FI, Lin YS, Lee JK, et al
    The Effects of Mineralocorticoid Receptor Antagonists on Cardiovascular Outcomes in Patients With End-Stage Renal Disease and Heart Failure.
    Eur J Heart Fail. 2022 Nov 20. doi: 10.1002/ejhf.2740.
    PubMed     Abstract available


  74. GARCIA-ALVAREZ A, Blanco I, Garcia-Lunar I, Jorda P, et al
    beta3-adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial.
    Eur J Heart Fail. 2022 Nov 20. doi: 10.1002/ejhf.2745.
    PubMed     Abstract available


  75. FAUVEL C, Bonnet G, Mullens W, Giraldo CIS, et al
    Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: an international cardiology survey.
    Eur J Heart Fail. 2022 Nov 20. doi: 10.1002/ejhf.2743.
    PubMed     Abstract available


  76. WHINNETT ZI, Shun-Shin MJ, Tanner M, Foley P, et al
    Effects of haemodynamically atrio-ventricular optimized His-pacing on heart failure symptoms and exercise capacity: The His Optimized Pacing Evaluated for Heart Failure (HOPE-HF) randomised, double-blind, cross-over trial.
    Eur J Heart Fail. 2022 Nov 20. doi: 10.1002/ejhf.2736.
    PubMed     Abstract available


  77. MOHEBI R, Liu Y, van Kimmenade R, Gaggin HK, et al
    Inflammation across Universal Definition of Heart Failure Stages: The CASABLANCA Study.
    Eur J Heart Fail. 2022 Nov 17. doi: 10.1002/ejhf.2742.
    PubMed     Abstract available


  78. PATEL HC, Kaye DM
    SGLT2i: Efficacious and Safe in Elderly Patients with Heart Failure.
    Eur J Heart Fail. 2022 Nov 17. doi: 10.1002/ejhf.2744.
    PubMed    


  79. VAN WOERDEN G, van Veldhuisen DJ, Westenbrink BD, de Boer RA, et al
    Connecting Epicardial Adipose Tissue and Heart Failure with Preserved Ejection Fraction: Mechanisms, Management and Modern Perspectives.
    Eur J Heart Fail. 2022 Nov 17. doi: 10.1002/ejhf.2741.
    PubMed     Abstract available


  80. PACKER M
    How Can SGLT2 Inhibitors Stimulate Erythrocytosis in Patients Who Are Iron Deficient? Implications for Understanding Iron Hemostasis in Heart Failure.
    Eur J Heart Fail. 2022 Nov 14. doi: 10.1002/ejhf.2731.
    PubMed     Abstract available


  81. DE BIASE N, Del Punta L, Pugliese NR
    The dangerous liaison between epicardial adipose tissue and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2022 Nov 14. doi: 10.1002/ejhf.2733.
    PubMed    


  82. FUCHS ANDERSEN C, Omar M, Glenthoj A, El Fassi D, et al
    Effects of Empagliflozin on Erythropoiesis in Heart Failure: Data from the Empire HF Trial.
    Eur J Heart Fail. 2022 Nov 14. doi: 10.1002/ejhf.2735.
    PubMed     Abstract available


  83. LERMAN JB, Felker GM
    Time to Diuretics in Acute Heart Failure: the tortoise or the hare?
    Eur J Heart Fail. 2022 Nov 9. doi: 10.1002/ejhf.2732.
    PubMed    


  84. PATEL RB, Greene SJ, Xu H, Alhanti B, et al
    Intersection of Atrial Fibrillation and Heart Failure with Mildly Reduced and Preserved Ejection Fraction in >400,000 Participants in the Get With The Guidelines Heart Failure Registry.
    Eur J Heart Fail. 2022 Nov 7. doi: 10.1002/ejhf.2729.
    PubMed     Abstract available


  85. YANG M, Butt JH, Kondo T, Jering KS, et al
    Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
    Eur J Heart Fail. 2022 Nov 7. doi: 10.1002/ejhf.2722.
    PubMed     Abstract available


  86. GREENE SJ, Goto D, Wang D, Hilkert R, et al
    Outpatient versus Inpatient Intravenous Diuretic Therapy for Heart Failure in the United States.
    Eur J Heart Fail. 2022 Nov 5. doi: 10.1002/ejhf.2727.
    PubMed    


  87. ANKER SD, Khan MS, Butler J, Ofstad AP, et al
    Weight Change and Clinical Outcomes in Heart Failure with Reduced Ejection Fraction: Insights from EMPEROR-Reduced.
    Eur J Heart Fail. 2022 Nov 2. doi: 10.1002/ejhf.2728.
    PubMed     Abstract available


  88. ADAMO M, Pagnesi M, Ghizzoni G, Estevez-Loureiro R, et al
    Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality.
    Eur J Heart Fail. 2022;24:2175-2184.
    PubMed     Abstract available


  89. TOMASONI D, Adamo M, Metra M
    November 2022 at a glance: focus on epidemiology, prognosis and comorbidities.
    Eur J Heart Fail. 2022;24:1997-1999.
    PubMed    


  90. MARTINO M, Sannino A
    From forgotten to rediscovered: shifting focus to the right ventricle in primary mitral regurgitation.
    Eur J Heart Fail. 2022;24:2172-2174.
    PubMed    


  91. JHUND PS
    Implementing the evidence - the true summit of evidence-based care and the false peak of guidelines.
    Eur J Heart Fail. 2022;24:2090-2092.
    PubMed    


  92. CEDARS A, Joseph S
    Don't tell your patients where they are, let them tell you.
    Eur J Heart Fail. 2022;24:2105-2107.
    PubMed    


  93. HEIDECKER B, Dagan N, Balicer R, Eriksson U, et al
    Myocarditis following COVID-19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ES
    Eur J Heart Fail. 2022;24:2000-2018.
    PubMed     Abstract available


  94. DOLDI PM, Stolz L, Kalbacher D, Koll B, et al
    Right ventricular dysfunction predicts outcome after transcatheter mitral valve repair for primary mitral valve regurgitation.
    Eur J Heart Fail. 2022;24:2162-2171.
    PubMed     Abstract available


  95. VERGARO G, Aimo A, Rapezzi C, Castiglione V, et al
    Atrial amyloidosis: mechanisms and clinical manifestations.
    Eur J Heart Fail. 2022;24:2019-2028.
    PubMed     Abstract available


  96. STANTON LJ, Dershowitz LB, Lang KJ, Brandwein R, et al
    Insights from a clinical heart valve centre: characteristics and management of functional mitral regurgitation.
    Eur J Heart Fail. 2022;24:2202-2205.
    PubMed    


  97. HIGUCHI S, Orban M, Adamo M, Giannini C, et al
    Guideline-directed medical therapy in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation.
    Eur J Heart Fail. 2022;24:2152-2161.
    PubMed     Abstract available


    October 2022
  98. FERREIRA JP, Cleland JG, Girerd N, Bozec E, et al
    Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
    Eur J Heart Fail. 2022 Oct 27. doi: 10.1002/ejhf.2726.
    PubMed     Abstract available


  99. BATRA G, Aktaa S, Benson L, Dahlstrom U, et al
    Association between heart failure quality of care and mortality: population-based cohort study using nationwide registries.
    Eur J Heart Fail. 2022 Oct 27. doi: 10.1002/ejhf.2725.
    PubMed     Abstract available


  100. PATEL KV, Khan MS, Segar MW, Bahnson JL, et al
    Optimal Cardiometabolic Health and Risk of Heart Failure in Type 2 Diabetes: An Analysis from the Look AHEAD Trial.
    Eur J Heart Fail. 2022 Oct 24. doi: 10.1002/ejhf.2723.
    PubMed     Abstract available


  101. ANSARI RAMANDI MM, van Melle JP, Gorter TM, Hoendermis ES, et al
    Right ventricular dysfunction in patients with new-onset heart failure: Longitudinal follow-up during guideline-directed medical therapy.
    Eur J Heart Fail. 2022 Oct 17. doi: 10.1002/ejhf.2721.
    PubMed     Abstract available


  102. BUTLER J, Usman MS, Anstrom KJ, Blaustein RO, et al
    Soluble Guanylate Cyclase Stimulators in Patients with Heart Failure with Reduced Ejection Fraction Across the Risk Spectrum.
    Eur J Heart Fail. 2022 Oct 17. doi: 10.1002/ejhf.2720.
    PubMed     Abstract available


  103. DE LA ESPRIELLA R, Bayes-Genis A, Nunez J
    Bending Oxygen Saturation index (BOSI) and Risk of Worsening Heart Failure Events in Chronic Heart Failure.
    Eur J Heart Fail. 2022 Oct 12. doi: 10.1002/ejhf.2717.
    PubMed    


  104. BRANCH KRH, Gerstein HC, Probstfield JL
    Letter regarding the article Dulaglutide and Cardiovascular and Heart Failure Outcomes in Patients With and Without Heart Failure: A Post-Hoc Analysis from the REWIND Randomized Trial: Reply.
    Eur J Heart Fail. 2022 Oct 12. doi: 10.1002/ejhf.2719.
    PubMed    


  105. ZHANG Y, Feng J, Zhang J
    Heart failure with preserved ejection fraction in China: An urgent need for improving the management.
    Eur J Heart Fail. 2022 Oct 11. doi: 10.1002/ejhf.2718.
    PubMed    


  106. SHI C, Aboumsallem JP, Suthahar N, de Graaf AO, et al
    Clonal hematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers.
    Eur J Heart Fail. 2022 Oct 11. doi: 10.1002/ejhf.2715.
    PubMed     Abstract available


  107. ZAKERI R, Ahluwalia N, Tindale A, Omar F, et al
    Long-term outcomes following catheter ablation versus medical therapy in patients with persistent atrial fibrillation and heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2022 Oct 11. doi: 10.1002/ejhf.2714.
    PubMed     Abstract available


  108. INCIARDI RM, Pagnesi M, Lombardi CM, Solomon SD, et al
    Reply to "Clinical implications of left atrial changes after optimization of medical therapy in heart failure patients".
    Eur J Heart Fail. 2022 Oct 11. doi: 10.1002/ejhf.2713.
    PubMed    


  109. VENKATESHVARAN A, Faxen UL, Hage C, Michaelsson E, et al
    Association of Epicardial Adipose Tissue with Proteomics, Coronary Flow Reserve, Cardiac Structure and Function, and Quality of Life in Heart Failure with Preserved Ejection Fraction: Insights from the PROMIS-HFpEF study.
    Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2709.
    PubMed     Abstract available


  110. OUWERKERK W, Tromp J, Cleland JGF, Angermann CE, et al
    Association of time-to-IV-furosemide with mortality in acute heart failure: data from REPORT-HF.
    Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2708.
    PubMed     Abstract available


  111. FILIPPATOS G, Anker SD, Butler J, Farmakis D, et al
    Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: A secondary analysis of EMPEROR-Reduced.
    Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2707.
    PubMed     Abstract available


  112. MIRANDA WR, Borlaug BA, Jain CC, Anderson JH, et al
    Exercise-induced changes in pulmonary artery wedge pressure in adults post-Fontan versus heart failure with preserved ejection fraction and noncardiac dyspnea.
    Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2706.
    PubMed     Abstract available


  113. MARTENS P
    Inhibiting the proximal nephron in acute heart failure - emerging data on kidney safety and efficacy.
    Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2711.
    PubMed    


  114. CHATUR S, Claggett BL, Vardeny O, Jering K, et al
    Sacubitril/Valsartan and Loop Diuretic Requirement in Heart Failure with Preserved Ejection Fraction in the PARAGON-HF Trial.
    Eur J Heart Fail. 2022 Oct 1. doi: 10.1002/ejhf.2703.
    PubMed     Abstract available


  115. ARONSON D
    Can subgroup analyses in randomized trials guide individualized patient care?
    Eur J Heart Fail. 2022;24:1802-1804.
    PubMed    


  116. CHATUR S, Lakdawala NK, Cunningham JW
    Random admission urinary sodium for diuretic response: promise in pragmatism?
    Eur J Heart Fail. 2022;24:1988-1989.
    PubMed    


  117. CHIONCEL O, Metra M
    Morphine in acute pulmonary oedema: a signal of harm but more questions than answers.
    Eur J Heart Fail. 2022;24:1963-1966.
    PubMed    


  118. BERWANGER O, Pfeffer M, Claggett B, Jering KS, et al
    Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.
    Eur J Heart Fail. 2022;24:1918-1927.
    PubMed     Abstract available


  119. BELDHUIS IE, Martens P, Ter Maaten JM
    Early changes in renal function after sodium-glucose cotransporter 2 inhibitor initiation in EMPEROR-Reduced: the end of the dilemma?
    Eur J Heart Fail. 2022;24:1840-1843.
    PubMed    


  120. PAPPALARDO F, Tavazzi G, Savonitto S, Morici N, et al
    Enrolling patients in cardiogenic shock trials: are we missing someone? Insights from the Italian AltShock-2 registry.
    Eur J Heart Fail. 2022;24:1748-1750.
    PubMed    


  121. MOHR E, Thum T, Bar C
    Accelerating cardiovascular research: recent advances in translational 2D and 3D heart models.
    Eur J Heart Fail. 2022;24:1778-1791.
    PubMed     Abstract available


  122. DOMINGUEZ-RODRIGUEZ A, Suero-Mendez C, Burillo-Putze G, Gil V, et al
    Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled trial.
    Eur J Heart Fail. 2022;24:1953-1962.
    PubMed     Abstract available


  123. ZANNAD F, Ferreira JP, Gregson J, Kraus BJ, et al
    Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced.
    Eur J Heart Fail. 2022;24:1829-1839.
    PubMed     Abstract available


    September 2022
  124. KEIR DA, Floras JS
    Iron repletion in heart failure: a central chemoreceptor reflex tonic?
    Eur J Heart Fail. 2022 Sep 25. doi: 10.1002/ejhf.2697.
    PubMed    


  125. BAEZA-TRINIDAD R, Mosquera-Lozano JD
    "Bending Oxygen Saturation Index (BOSI) and Risk of Worsening Heart Failure Events in Chronic Heart Failure": A letter to the editor.
    Eur J Heart Fail. 2022 Sep 25. doi: 10.1002/ejhf.2701.
    PubMed    


  126. PARVAN R, Hosseinpour M, Moradi Y, Devaux Y, et al
    Diagnostic Performance of MicroRNAs in the Detection of Heart Failure with Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
    Eur J Heart Fail. 2022 Sep 25. doi: 10.1002/ejhf.2700.
    PubMed     Abstract available


  127. LEE MMY, Campbell RT, Claggett BL, Lewis EF, et al
    Health-related quality of life in acute heart failure: Association between patient-reported symptoms and markers of congestion.
    Eur J Heart Fail. 2022 Sep 25. doi: 10.1002/ejhf.2699.
    PubMed     Abstract available


  128. PELLICORI P, Kalra PR, Clark AL, Friday JM, et al
    CKD and CKD-ism in heart failure - what a mess!
    Eur J Heart Fail. 2022 Sep 21. doi: 10.1002/ejhf.2696.
    PubMed    



  129. Corrigendum to 'Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata' [Eur J Heart Fail 2022;24:1047-1062].
    Eur J Heart Fail. 2022 Sep 20. doi: 10.1002/ejhf.2691.
    PubMed    


  130. FERREIRA JP, Neves JS
    Letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.
    Eur J Heart Fail. 2022 Sep 17. doi: 10.1002/ejhf.2694.
    PubMed    


  131. COOPER TJ, Pellicori P, Ushakova A, Dickstein K, et al
    Reply to the letter "Particular Challenges in the Use of Pulmonary Vasodilating Therapy for Patients with Pulmonary Hypertension Secondary to Left Heart Diseases".
    Eur J Heart Fail. 2022 Sep 17. doi: 10.1002/ejhf.2690.
    PubMed    


  132. VAN ESSEN BJ, Tromp J, Ter Maaten JM, Greenberg BH, et al
    Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction.
    Eur J Heart Fail. 2022 Sep 16. doi: 10.1002/ejhf.2695.
    PubMed     Abstract available


  133. DE LA ESPRIELLA R, Bayes-Genis A, Nunez J
    Bending Oxygen Saturation index (BOSI) and Risk of Worsening Heart Failure Events in Chronic Heart Failure.
    Eur J Heart Fail. 2022 Sep 14. doi: 10.1002/ejhf.2692.
    PubMed    


  134. FERREIRA JP, Neves JS
    Glucagon-Like Peptide 1 Receptor Agonists in Heart Failure: the need for a rewind.
    Eur J Heart Fail. 2022 Sep 14. doi: 10.1002/ejhf.2693.
    PubMed    


  135. JOURY A, Razaghizad A, Sharma A
    Multi-Biomarkers Approach to Predict Survival and Adverse Cardiovascular Events Among Patients with Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2022 Sep 13. doi: 10.1002/ejhf.2689.
    PubMed    



  136. Corrigendum to 'Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction' [Eur J Heart Fail 2022;24:782-790].
    Eur J Heart Fail. 2022 Sep 13. doi: 10.1002/ejhf.2676.
    PubMed    


  137. GREENE SJ, Fonarow GC, Butler J
    SGLT2 Inhibitors for Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Time to Deliver Implementation.
    Eur J Heart Fail. 2022 Sep 13. doi: 10.1002/ejhf.2688.
    PubMed    


  138. ADAMSON C, Jhund PS, McMurray JJ
    Reply: Liver function tests and outcomes in heart failure with reduced ejection fraction: Findings from DAPA-HF.
    Eur J Heart Fail. 2022 Sep 12. doi: 10.1002/ejhf.2683.
    PubMed    


  139. MCDOWELL K, Jhund PS, McMurray JJ
    Reply to 'Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials'. Letter regarding the article 'Dapagliflozin reduces uric acid concentrat
    Eur J Heart Fail. 2022 Sep 12. doi: 10.1002/ejhf.2686.
    PubMed    


  140. GIRERD N
    Worsening renal function precedes and follows worsening heart failure.
    Eur J Heart Fail. 2022 Sep 11. doi: 10.1002/ejhf.2673.
    PubMed    


  141. BUTLER J, Siddiqi TJ, Anker SD
    Patiromer Use in Patients with Heart Failure Lessons and Clinical Considerations from the DIAMOND Trial.
    Eur J Heart Fail. 2022 Sep 11. doi: 10.1002/ejhf.2684.
    PubMed    


  142. BOHM M, Butler J, Mahfoud F, Filippatos G, et al
    Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2022 Sep 10. doi: 10.1002/ejhf.2677.
    PubMed     Abstract available


  143. BRANCH KRH, Dagenais GR, Avezum A, Basile J, et al
    Dulaglutide and Cardiovascular and Heart Failure Outcomes in Patients With and Without Heart Failure: A Post-hoc Analysis from the REWIND Randomized Trial.
    Eur J Heart Fail. 2022 Sep 8. doi: 10.1002/ejhf.2670.
    PubMed     Abstract available


  144. BAYES-GENIS A, Aimo A, Jhund P, Richards AM, et al
    A review from the Biomarkers Working Group of the Heart Failure Association of the ESC: A review from the Biomarkers Working Group of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2022 Sep 8. doi: 10.1002/ejhf.2675.
    PubMed     Abstract available


  145. VOORS AA, Damman K, Teerlink JR, Angermann CE, et al
    Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.
    Eur J Heart Fail. 2022 Sep 6. doi: 10.1002/ejhf.2681.
    PubMed     Abstract available


  146. NAHAR TAK, Shah A, Ahmad M
    "Bending Oxygen Saturation Index (BOSI) and Risk of Worsening Heart Failure Events in Chronic Heart Failure": A letter to the editor.
    Eur J Heart Fail. 2022 Sep 6. doi: 10.1002/ejhf.2679.
    PubMed    


  147. KRAWCZYK M, Bohm M
    The 50 shades of bilirubin.
    Eur J Heart Fail. 2022 Sep 6. doi: 10.1002/ejhf.2671.
    PubMed    


  148. LUND LH, Eldhagen P
    Diagnosing heart failure with preserved ejection fraction in cardiac amyloidosis or diagnosing cardiac amyloidosis in heart failure with preserved ejection fraction?
    Eur J Heart Fail. 2022 Sep 6. doi: 10.1002/ejhf.2678.
    PubMed    


  149. XIE C, Zhang Y, Lin J
    What is the optimal dose of neurohormonal modulators in patients with heart failure? The higher the better?
    Eur J Heart Fail. 2022 Sep 4. doi: 10.1002/ejhf.2668.
    PubMed    


  150. JHUND PS
    Cardiopulmonary functional capacity: Another piece of the puzzle of SGLT2 inhibition in heart failure?
    Eur J Heart Fail. 2022 Sep 2. doi: 10.1002/ejhf.2672.
    PubMed    


  151. TOMASONI D, Adamo M, Metra M
    September 2022 at a glance.
    Eur J Heart Fail. 2022;24:1455-1457.
    PubMed    


  152. ROSANO GMC, Metra M, Volterrani M
    The strategic vision of the 2022-2024 mandate - greater involvement of members, young specialists for an HFA community without borders.
    Eur J Heart Fail. 2022;24:1458-1459.
    PubMed    


  153. MEEKERS E, Mullens W
    When is the time right? Dancing on the tightrope: referral for upgrade to cardiac resynchronization therapy.
    Eur J Heart Fail. 2022;24:1662-1664.
    PubMed    


  154. BUTT JH, McMurray JJV
    Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients.
    Eur J Heart Fail. 2022;24:1623-1624.
    PubMed    


  155. PORCARI A, Merlo M, Sinagra G
    Time to reconsider thromboembolic risk and anticoagulation in transthyretin cardiac amyloidosis?
    Eur J Heart Fail. 2022;24:1716-1718.
    PubMed    


  156. MUSIGK N, Heidecker B
    Transthyretin amyloidosis: the picture is getting clearer.
    Eur J Heart Fail. 2022;24:1697-1699.
    PubMed    


  157. NITSCHE C
    Echocardiographic tracking of transthyretin cardiomyopathy: which parameters matter the most?
    Eur J Heart Fail. 2022;24:1713-1715.
    PubMed    


  158. BAUERSACHS J, Koenig T
    Peripartum cardiomyopathy - a global challenge.
    Eur J Heart Fail. 2022;24:1737-1738.
    PubMed    


  159. ALVAREZ-GARCIA J
    Sacubitril/valsartan adherence... because the best is sometimes difficult to replace the good.
    Eur J Heart Fail. 2022;24:1516-1518.
    PubMed    


  160. DENIAU B, Asakage A, Mebazaa A
    Clonal haematopoiesis mutations in cardiogenic shock: a beginning of a new era?
    Eur J Heart Fail. 2022;24:1583-1585.
    PubMed    


  161. BURTON JO, Coats AJS, Kovesdy CP, Palmer BF, et al
    An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum.
    Eur J Heart Fail. 2022;24:1467-1477.
    PubMed     Abstract available


  162. CHACKO L, Karia N, Venneri L, Bandera F, et al
    Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2022;24:1700-1712.
    PubMed     Abstract available


  163. HOEVELMANN J, Engel ME, Muller E, Hohlfeld A, et al
    A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic review and meta-analysis.
    Eur J Heart Fail. 2022;24:1719-1736.
    PubMed     Abstract available


  164. ANTONOPOULOS AS, Panagiotopoulos I, Kouroutzoglou A, Koutsis G, et al
    Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
    Eur J Heart Fail. 2022;24:1677-1696.
    PubMed     Abstract available


  165. SCOLARI FL, Abelson S, Brahmbhatt DH, Medeiros JJF, et al
    Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock.
    Eur J Heart Fail. 2022;24:1573-1582.
    PubMed     Abstract available


    August 2022
  166. NUNEZ J, de la Espriella R, Rossignol P, Voors AA, et al
    Congestion in Heart Failure: a circulating biomarker-based perspective.
    Eur J Heart Fail. 2022 Aug 30. doi: 10.1002/ejhf.2664.
    PubMed     Abstract available


  167. PATEL HC, Kaye DM
    The rise of devices in heart failure with preserved ejection fraction: the future is not set.
    Eur J Heart Fail. 2022 Aug 29. doi: 10.1002/ejhf.2667.
    PubMed    


  168. NAITO R, Kasai T
    Obstructive coronary artery disease, a common and curable but critical comorbidity in acute decompensated heart failure.
    Eur J Heart Fail. 2022 Aug 29. doi: 10.1002/ejhf.2665.
    PubMed    


  169. DOEHNER W, Packer M
    Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials. Letter regarding the article 'Dapagliflozin reduces uric acid concentration, an ind
    Eur J Heart Fail. 2022 Aug 29. doi: 10.1002/ejhf.2666.
    PubMed    


  170. SINAGRA G, Paldino A, Dal Ferro M
    HEART FAILURE WITH SUPRA-NORMAL LEFT VENTRICLE EJECTION FRACTION: DISTINCT POLYGENIC BASES OF AN UNRECOGNIZED PHENOTYPE.
    Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2657.
    PubMed    


  171. ZITO A, Princi G, Romiti GF, Galli M, et al
    Device-based remote monitoring strategies for congestion-guided management of patients with heart failure: a systematic review and meta-analysis.
    Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2655.
    PubMed     Abstract available


  172. ASSMUS B, Angermann CE, Alkhlout B, Asselbergs FW, et al
    Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension: Insights from the MEMS-HF study.
    Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2656.
    PubMed     Abstract available


  173. MARTENS P, Chen HH, Verbrugge FH, Testani JT, et al
    Assessing Intrinsic Renal Sodium Avidity in Acute Heart Failure: Implications in Predicting and Guiding Decongestion.
    Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2662.
    PubMed     Abstract available


  174. CAI A, Qiu W, Zhou Y, Feng Y, et al
    Clinical characteristics and 1-year outcomes in hospitalized patients with heart failure with preserved ejection fraction: Results from the China Cardiovascular Association Database-Heart Failure Center Registry.
    Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2654.
    PubMed     Abstract available


  175. FERREIRA JP, Sharma A, Vasques-Novoa F, Angelico-Goncalves A, et al
    Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes.
    Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2660.
    PubMed     Abstract available


  176. OSTROMINSKI JW, Vaduganathan M, Claggett BL, de Boer RA, et al
    Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
    Eur J Heart Fail. 2022 Aug 11. doi: 10.1002/ejhf.2652.
    PubMed     Abstract available


  177. RICHARDS AM
    Optimizing the diagnostic utility of NT-proBNP for acute heart failure in obesity and beyond.
    Eur J Heart Fail. 2022 Aug 9. doi: 10.1002/ejhf.2653.
    PubMed    


  178. ADAMSON C, Cowan LM, de Boer RA, Diez M, et al
    Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF.
    Eur J Heart Fail. 2022 Aug 6. doi: 10.1002/ejhf.2649.
    PubMed     Abstract available


  179. DE LA ESPRIELLA R, Amiguet M, Minana G, Rodriguez JC, et al
    Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure.
    Eur J Heart Fail. 2022 Aug 6. doi: 10.1002/ejhf.2651.
    PubMed     Abstract available


  180. ANTOHI LE, Adamo M, Chioncel O
    Long-term Survival after Acute Heart Failure Hospitalization; From Observation to Collaborative Interventions.
    Eur J Heart Fail. 2022 Aug 2. doi: 10.1002/ejhf.2645.
    PubMed    


  181. LINDBERG F, Lund LH, Benson L, Dahlstrom U, et al
    Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2022 Aug 2. doi: 10.1002/ejhf.2644.
    PubMed     Abstract available


  182. TOMASONI D, Adamo M, Metra M
    August 2022 at a glance: focus on heart failure with preserved ejection fraction and cardiac amyloidosis.
    Eur J Heart Fail. 2022;24:1325-1326.
    PubMed    


  183. CHANDRAMOULI C, Lam CSP
    Sex, fat and the heart: it's all in the waist.
    Eur J Heart Fail. 2022;24:1371-1376.
    PubMed    


  184. RUBIO-INFANTE N, Ramirez-Flores YA, Castillo EC, Lozano O, et al
    Methodological and reporting issues for meta-analysis of immune checkpoint inhibitor-associated cardiotoxicity. Letter regarding the article 'Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis'. Reply.
    Eur J Heart Fail. 2022;24:1450-1451.
    PubMed    


  185. CLEMMENSEN TS, Poulsen SH
    Systemic embolism in transthyretin amyloid cardiomyopathy: how to look into the future.
    Eur J Heart Fail. 2022;24:1397-1399.
    PubMed    


  186. VILCHES S, Fontana M, Gonzalez-Lopez E, Mitrani L, et al
    Systemic embolism in amyloid transthyretin cardiomyopathy.
    Eur J Heart Fail. 2022;24:1387-1396.
    PubMed     Abstract available


  187. JERING KS, Campagnari C, Claggett B, Adler E, et al
    Improving clinical trial efficiency using a machine learning-based risk score to enrich study populations.
    Eur J Heart Fail. 2022;24:1418-1426.
    PubMed     Abstract available


  188. MERLO M, Pagura L, Porcari A, Cameli M, et al
    Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey.
    Eur J Heart Fail. 2022;24:1377-1386.
    PubMed     Abstract available


    July 2022
  189. BORIANI G, Vitolo M, Imberti JF
    Effectiveness of atrial fibrillation ablation in heart failure across the entire spectrum of left ventricular ejection fraction.
    Eur J Heart Fail. 2022 Jul 29. doi: 10.1002/ejhf.2642.
    PubMed    


  190. CHATUR S, Vaduganathan M, Peikert A, Claggett BL, et al
    Longitudinal Trajectories in Renal Function Before and After Heart Failure Hospitalization Among Patients with HFpEF in the PARAGON-HF Trial.
    Eur J Heart Fail. 2022 Jul 27. doi: 10.1002/ejhf.2638.
    PubMed     Abstract available


  191. METRA M, Jankowska EA, Pagnesi M, Anker SD, et al
    Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.
    Eur J Heart Fail. 2022 Jul 23. doi: 10.1002/ejhf.2630.
    PubMed    


  192. VADUGANATHAN M, Ferreira JP, Rossignol P, Neuen B, et al
    Effects of Steroidal Mineralocorticoid Receptor Antagonists on Acute and Chronic Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Heart Failure.
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2635.
    PubMed     Abstract available


  193. SALAH HM, Fudim M
    Tolerability and Safety Barriers of SGLT2 Inhibitors Initiation in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2633.
    PubMed    


  194. BROMAGE DI, Cannata A, McDonagh TA
    Combination diuretic therapy for acute heart failure: "Alone we can do so little; together we can do so much".
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2634.
    PubMed    


  195. METRA M, Chioncel O, Cotter G, Davison B, et al
    Safety and Efficacy of Istaroxime for Patients with Acute-Heart-Failure-Related Pre-cardiogenic Shock - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study (SEISMiC).
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2629.
    PubMed     Abstract available


  196. CARAVITA S, Faini A, Vignati C, Pelucchi S, et al
    Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure.
    Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2628.
    PubMed     Abstract available


  197. LINDE C, Grabowski M, Ponikowski P, Rao I, et al
    Cardiac Contractility Modulation Therapy Improves Health Status in Patients with Heart Failure with Preserved Ejection Fraction; a Pilot Study (CCM-HFpEF).
    Eur J Heart Fail. 2022 Jul 20. doi: 10.1002/ejhf.2619.
    PubMed     Abstract available


  198. TOMASONI D, Aimo A, Merlo M, Nardi M, et al
    Value of the HFA-PEFF and H2 FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis.
    Eur J Heart Fail. 2022 Jul 20. doi: 10.1002/ejhf.2616.
    PubMed     Abstract available


  199. PAPALIA F, Charles-Edwards G, Okonko DO
    Reply to the letter regarding the article "Cardiac Energetics in Patients with Chronic Heart Failure and Iron Deficiency: An in-vivo 31P Magnetic Resonance Study".
    Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2625.
    PubMed    


  200. DANDEL M, Hetzer R
    Particular Challenges in the Use of Pulmonary Vasodilating Therapy for Patients with Pulmonary Hypertension Secondary to Left Heart Diseases.
    Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2622.
    PubMed    


  201. GENTILE F, Passino C, Emdin M, Giannoni A, et al
    Baroreflex activation therapy in heart failure: targeting the right patient.
    Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2627.
    PubMed    


  202. REDDY YNV, Sundaram V
    Spironolactone, fibrosis and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2626.
    PubMed    


  203. KRISTENSEN SL, Gustafsson F
    Advanced Heart Failure: time to screen?
    Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2624.
    PubMed    


  204. JANSE RJ, Fu EL, Dahlstrom U, Benson L, et al
    Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence.
    Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2620.
    PubMed     Abstract available


  205. CHUNAWALA ZS, Qamar A, Arora S, Pandey A, et al
    Prognostic significance of obstructive coronary artery disease in patients admitted with acute decompensated heart failure: The ARIC study community surveillance.
    Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2617.
    PubMed     Abstract available


  206. KOZHUHAROV N, Martin J, Wussler D, Lopez-Ayala P, et al
    Clinical Effect of Obesity on NT-proBNP Cut-off Concentrations for the Diagnosis of Acute Heart Failure.
    Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2618.
    PubMed     Abstract available


  207. POCOCK SJ, Ferreira JP, Packer M, Zannad F, et al
    Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Eur J Heart Fail. 2022 Jul 7. doi: 10.1002/ejhf.2607.
    PubMed     Abstract available


  208. MERKELY B, Geller L, Zima E, Osztheimer I, et al
    Baseline clinical characteristics of heart failure patients with reduced ejection fraction enrolled in the BUDAPEST-CRT Upgrade trial.
    Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2609.
    PubMed     Abstract available


  209. SENNI M, Alemayehu WG, Sim D, Edelmann F, et al
    Efficacy and Safety of Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/Valsartan: Insights from the VICTORIA Trial.
    Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2608.
    PubMed     Abstract available


  210. WANG X, Cunningham JW
    Restoring Balance in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2599.
    PubMed    


  211. KRISTENSEN SL, Barasa A, Thune JJ
    The Challenge of Addressing Heart Failure in Low and Middle Income Countries.
    Eur J Heart Fail. 2022 Jul 4. doi: 10.1002/ejhf.2598.
    PubMed    


  212. BAYES-GENIS A, Aimo A, Lupon J
    Empagliflozin in heart failure with preserved and mildly reduced ejection fraction: prognostic benefit confirmed with different endpoint definitions.
    Eur J Heart Fail. 2022 Jul 4. doi: 10.1002/ejhf.2597.
    PubMed    


  213. GULIZIA MM, Orso F, Mortara A, Lucci D, et al
    BLITZ-HF: a nationwide initiative to evaluate and improve adherence to acute and chronic heart failure guidelines.
    Eur J Heart Fail. 2022 Jul 3. doi: 10.1002/ejhf.2605.
    PubMed     Abstract available


  214. VON OLSHAUSEN G, Benson L, Dahlstrom U, Lund LH, et al
    Catheter Ablation for Patients with Atrial Fibrillation and Heart Failure: Insights from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2022 Jul 2. doi: 10.1002/ejhf.2604.
    PubMed     Abstract available


  215. VRTOVEC B, Frljak S, Poglajen G, Zemljic G, et al
    A PILOT CLINICAL TRIAL OF CELL THERAPY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION.
    Eur J Heart Fail. 2022 Jul 1. doi: 10.1002/ejhf.2596.
    PubMed     Abstract available


  216. MARCO GUAZZI M, Wilhelm M, Halle M, Van Craenenbroeck E, et al
    Exercise Testing in HFpEF: an Appraisal Through Diagnosis, Pathophysiology and Therapy A Clinical Consensus Statement of the Heart Failure Association (HFA) and European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology
    Eur J Heart Fail. 2022 Jul 1. doi: 10.1002/ejhf.2601.
    PubMed     Abstract available



  217. Abstracts of the Heart Failure 2022 and the World Congress on Acute Heart Failure, 21 - 24 May 2022, Madrid, Spain.
    Eur J Heart Fail. 2022;24 Suppl 2:3-282.
    PubMed    


  218. TOMASONI D, Adamo M, Metra M
    July 2022 at a glance: focus on prognosis, devices and valvular heart disease.
    Eur J Heart Fail. 2022;24:1145-1147.
    PubMed    


  219. SCHRAGE B, Westermann D
    Enough iron in transcatheter aortic valve implantation already.
    Eur J Heart Fail. 2022;24:1280-1281.
    PubMed    


  220. DOMINGUEZ F
    Predicting pacemaker implantation in cardiac amyloidosis: let's start with an ECG.
    Eur J Heart Fail. 2022;24:1237-1238.
    PubMed    


  221. MCGURK KA, Halliday BP
    Dilated cardiomyopathy - details make the difference.
    Eur J Heart Fail. 2022;24:1197-1199.
    PubMed    


  222. PETUTSCHNIGG J, Edelmann F
    Closing the gap, or the beauty of alleviating our patients' symptoms.
    Eur J Heart Fail. 2022;24:1302-1304.
    PubMed    


  223. BORIANI G, Vitolo M, Leyva F
    Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: what are the barriers to implementation in the 'real world'?
    Eur J Heart Fail. 2022;24:1223-1226.
    PubMed    


  224. NAYAK A, Mehra MR
    Global challenges in left ventricular assist device therapy: a tale across two continents.
    Eur J Heart Fail. 2022;24:1316-1318.
    PubMed    


  225. ILIADIS C, Kalbacher D, Lurz P, Petrescu AM, et al
    Left atrial volume index and outcome after transcatheter edge-to-edge valve repair for secondary mitral regurgitation.
    Eur J Heart Fail. 2022;24:1282-1292.
    PubMed     Abstract available


  226. KVASLERUD AB, Bardan S, Andresen K, Klove SF, et al
    Intravenous iron supplement for iron deficiency in patients with severe aortic stenosis scheduled for transcatheter aortic valve implantation: results of the IIISAS randomised trial.
    Eur J Heart Fail. 2022;24:1269-1279.
    PubMed     Abstract available


  227. PORCARI A, Rossi M, Cappelli F, Canepa M, et al
    Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2022;24:1227-1236.
    PubMed     Abstract available


  228. JAKUS N, Brugts JJ, Claggett B, Timmermans P, et al
    Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registry.
    Eur J Heart Fail. 2022;24:1305-1315.
    PubMed     Abstract available


  229. MIRELIS JG, Escobar-Lopez L, Ochoa JP, Espinosa MA, et al
    Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy.
    Eur J Heart Fail. 2022;24:1183-1196.
    PubMed     Abstract available


  230. MANCA P, Stolfo D, Merlo M, Gregorio C, et al
    Transient versus persistent improved ejection fraction in non-ischaemic dilated cardiomyopathy.
    Eur J Heart Fail. 2022;24:1171-1179.
    PubMed     Abstract available


  231. STOCKER TJ, Cohen DJ, Arnold SV, Sommer S, et al
    Durability of benefit after transcatheter tricuspid valve intervention: insights from actigraphy.
    Eur J Heart Fail. 2022;24:1293-1301.
    PubMed     Abstract available


    June 2022
  232. ABDELHAMID M, Rosano G, Metra M, Adamopoulos S, et al
    Prevention of sudden death in heart failure with reduced ejection fraction: Do we still need ICD for primary prevention?
    Eur J Heart Fail. 2022 Jun 26. doi: 10.1002/ejhf.2594.
    PubMed     Abstract available


  233. HARIHARAPUTHIRAN S, Peng Y, Ngo L, Ali A, et al
    Long-term Survival and Life Expectancy Following an Acute Heart Failure Hospitalisation in Australia and New Zealand.
    Eur J Heart Fail. 2022 Jun 24. doi: 10.1002/ejhf.2595.
    PubMed     Abstract available


  234. INCIARDI RM, Pagnesi M, Lombardi CM, Anker SD, et al
    Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure.
    Eur J Heart Fail. 2022 Jun 24. doi: 10.1002/ejhf.2593.
    PubMed     Abstract available


  235. MULLENS W, Dauw J, Martens P, Meekers E, et al
    Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): Baseline Characteristics.
    Eur J Heart Fail. 2022 Jun 22. doi: 10.1002/ejhf.2587.
    PubMed     Abstract available


  236. VUKADINOVIC D, Abdin A, Anker SD, Rosano GM, et al
    Side effects and treatment initiation barriers of SGLT2 inhibitors in heart failure: A systematic review and meta-analysis.
    Eur J Heart Fail. 2022 Jun 22. doi: 10.1002/ejhf.2584.
    PubMed     Abstract available


  237. RYAN M, Perera D, Petrie MC
    Revascularization and heart failure with preserved ejection fraction - time for randomized trials.
    Eur J Heart Fail. 2022 Jun 21. doi: 10.1002/ejhf.2583.
    PubMed    


  238. REDDY YNV
    Moving beyond the Vasodilator Model in Heart Failure with reduced Ejection Fraction - Lessons from Sildenafil.
    Eur J Heart Fail. 2022 Jun 19. doi: 10.1002/ejhf.2582.
    PubMed    


  239. AIMO A, Castiglione V, Bayes-Genis A
    Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure?
    Eur J Heart Fail. 2022 Jun 19. doi: 10.1002/ejhf.2580.
    PubMed    


  240. COATS A, Abraham WT, Zile MR, Lindenfeld JA, et al
    Baroreflex activation therapy with the barostim device in patients with heart failure with reduced ejection fraction: A patient level meta-analysis of randomized controlled trials.
    Eur J Heart Fail. 2022 Jun 17. doi: 10.1002/ejhf.2573.
    PubMed     Abstract available


  241. KOBAYASHI M, Girerd N, Ferreira JP, Kevin D, et al
    The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2579.
    PubMed     Abstract available


  242. BURRAGE MK, Valkovic L, Rider OJ
    Letter regarding the article "Cardiac Energetics in Patients with Chronic Heart Failure and Iron Deficiency: An in-vivo 31P Magnetic Resonance Study".
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2574.
    PubMed    


  243. SEFEROVIC P, Farmakis D, Bayes-Genis A, Ben Gal T, et al
    Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2575.
    PubMed     Abstract available


  244. LUND LH, Pitt B, Metra M
    Left ventricular ejection fraction as the primary heart failure phenotyping parameter.
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2576.
    PubMed    


  245. INCIARDI RM, Chandra A
    Epicardial Adipose Tissue in Heart Failure: Risk Factor or Mediator?
    Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2577.
    PubMed    


  246. BHATT AS, Vaduganathan M, Solomon SD, Schneeweiss S, et al
    Sacubitril/Valsartan Use Patterns among Older Adults with Heart Failure in Clinical Practice: A Population-Based Cohort Study of >25,000 Medicare Beneficiaries.
    Eur J Heart Fail. 2022 Jun 11. doi: 10.1002/ejhf.2572.
    PubMed     Abstract available


  247. RAGAVAN A, Hogan J, Halliday BP
    The spectrum of heart failure with improved ejection fraction - persistent congestion, to heart failure remission and perhaps recovery?
    Eur J Heart Fail. 2022 Jun 6. doi: 10.1002/ejhf.2571.
    PubMed    


  248. HAVAKUK O, Topilsky Y
    The Impact of Early Surgery on Mortality in Infective Endocarditis Complicated by Heart Failure - How Much More Data Do We Need?
    Eur J Heart Fail. 2022 Jun 1. doi: 10.1002/ejhf.2567.
    PubMed    


  249. TOMASONI D, Adamo M, Metra M
    June 2022 at a glance: prevention, outcomes and treatment.
    Eur J Heart Fail. 2022;24:913-915.
    PubMed    


  250. LEYVA F, Boriani G
    The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: insights from an individual patient data meta-analysis of COMPANION and CARE-HF.
    Eur J Heart Fail. 2022;24:1091-1093.
    PubMed    


  251. COOPER LT JR
    Sex and autoimmunity in acute myocarditis: time for a refresh.
    Eur J Heart Fail. 2022;24:1045-1046.
    PubMed    


  252. CLELAND JGF, Bristow MR, Freemantle N, Olshansky B, et al
    The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF.
    Eur J Heart Fail. 2022;24:1080-1090.
    PubMed     Abstract available


  253. YAMAMOTO M, Tajiri K, Ayuzawa S, Ieda M, et al
    Pathological findings of clinically suspected myocarditis temporally associated with COVID-19 vaccination.
    Eur J Heart Fail. 2022;24:1132-1138.
    PubMed     Abstract available


  254. BARITUSSIO A, Schiavo A, Basso C, Giordani AS, et al
    Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies.
    Eur J Heart Fail. 2022;24:1033-1044.
    PubMed     Abstract available


  255. GONZALEZ A, Richards AM, de Boer RA, Thum T, et al
    Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2022;24:927-943.
    PubMed     Abstract available


  256. MARTENS P, Dupont M, Dauw J, Nijst P, et al
    The effect of intravenous ferric carboxymaltose on right ventricular function - insights from the IRON-CRT trial.
    Eur J Heart Fail. 2022;24:1106-1113.
    PubMed     Abstract available


  257. CHIANG CH, Chiang CH, Chiang CH
    Methodological and reporting issues for meta-analysis of immune checkpoint inhibitor-associated cardiotoxicity. Letter regarding the article 'Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis'.
    Eur J Heart Fail. 2022;24:1142-1143.
    PubMed    


  258. MCDOWELL K, Welsh P, Docherty KF, Morrow DA, et al
    Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.
    Eur J Heart Fail. 2022;24:1066-1076.
    PubMed     Abstract available


    May 2022

  259. Corrigendum to 'A population-based study of 92 clinicallyrecognized risk factors for heart failure: co-occurrence, prognosis and preventive potential' [Eur J Heart Fail 2022;24:466-480].
    Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2544.
    PubMed    


  260. ANKER SD, Siddiqi TJ, Filippatos G, Zannad F, et al
    Outcomes with Empagliflozin in Heart Failure with Preserved Ejection Fraction Using DELIVER-like Endpoint Definitions.
    Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2558.
    PubMed     Abstract available


  261. PALAU P, Amiguet M, Dominguez E, Sastre C, et al
    Short-term Effects of Dapagliflozin on Maximal Functional Capacity in Heart Failure with Reduced Ejection Fraction (DAPA-VO2 ): A Randomized Clinical Trial.
    Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2560.
    PubMed     Abstract available


  262. PAGNESI M, Lombardi CM, Chiarito M, Stolfo D, et al
    Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: Results from the HELP-HF Registry.
    Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2561.
    PubMed     Abstract available


  263. SORIMACHI H, Omote K, Omar M, Popovic D, et al
    Sex and Central Obesity in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2022 May 22. doi: 10.1002/ejhf.2563.
    PubMed     Abstract available


  264. INCIARDI RM, Bonelli A, Biering-Sorensen T, Cameli M, et al
    Left atrial disease and left atrial reverse remodeling across different stages of heart failure development and progression: a new target for prevention and treatment.
    Eur J Heart Fail. 2022 May 22. doi: 10.1002/ejhf.2562.
    PubMed     Abstract available


  265. FUDIM M, Fail PS, Litwin SE, Shaburishvili T, et al
    Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Early Results of the REBALANCE-HF Trial Roll-in Cohort.
    Eur J Heart Fail. 2022 May 22. doi: 10.1002/ejhf.2559.
    PubMed     Abstract available


  266. COOPER TJ, Cleland JG, Guazzi M, Pellicori P, et al
    Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (The SilHF study): A randomised placebo-controlled multicentre trial.
    Eur J Heart Fail. 2022 May 21. doi: 10.1002/ejhf.2527.
    PubMed     Abstract available


  267. RAVERA A, Santema BT, de Boer RA, Anker SD, et al
    Distinct pathophysiological pathways in women and men with heart failure.
    Eur J Heart Fail. 2022 May 21. doi: 10.1002/ejhf.2534.
    PubMed     Abstract available


  268. JANUS SE, Hajjari J, Chami T, Mously H, et al
    Multi-Variable Biomarker Approach in Identifying Incident Heart Failure in Chronic Kidney Disease Results from the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Eur J Heart Fail. 2022 May 19. doi: 10.1002/ejhf.2543.
    PubMed     Abstract available


  269. BAYES-GENIS A, Aimo A, Metra M, Anker S, et al
    Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA Heart Failure Guidelines.
    Eur J Heart Fail. 2022 May 17. doi: 10.1002/ejhf.2542.
    PubMed     Abstract available


  270. JOHANSSON I, Balasubramanian K, Bangdiwala S, Mielniczuk L, et al
    Factors associated with health-related quality of life in heart failure in 23,000 patients from 40 countries: Results of the G-CHF Research Program.
    Eur J Heart Fail. 2022 May 15. doi: 10.1002/ejhf.2535.
    PubMed     Abstract available


  271. NATH M, Romaine SP, Koekemoer A, Hamby S, et al
    Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure.
    Eur J Heart Fail. 2022 May 15. doi: 10.1002/ejhf.2540.
    PubMed     Abstract available


  272. VAN ESSEN B, Voors AA, Tromp J
    Risk factors for the development of heart failure in patients with or without prior myocardial infarction.
    Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2538.
    PubMed    


  273. ASLEH R, Briasoulis A, Borlaug BA
    Nonsteroidal Aldosterone Receptor Antagonism: A "Fine" Treatment for Heart Failure Patients?
    Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2537.
    PubMed    


  274. DAMMAN K
    When two worlds collide - Making sense of changes in renal function with life saving heart failure therapies.
    Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2539.
    PubMed    


  275. MYHRE PL, Claggett BL, Shah AM, Prescott MF, et al
    Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial.
    Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2541.
    PubMed     Abstract available


  276. BOHBOT Y, Habib G, Laroche C, Stohr E, et al
    Characteristics, management, and outcomes of patients with left-sided infective endocarditis complicated by heart failure: A substudy of the ESC-EORP EURO-ENDO (European infective endocarditis) registry.
    Eur J Heart Fail. 2022 May 4. doi: 10.1002/ejhf.2525.
    PubMed     Abstract available


  277. SCHRAGE B, Lund LH, Benson L, Dahlstrom U, et al
    Predictors of primary prevention implantable cardioverter defibrillator use in heart failure with reduced ejection fraction: Impact of the predicted risk of sudden cardiac death and all-cause mortality.
    Eur J Heart Fail. 2022 May 3. doi: 10.1002/ejhf.2530.
    PubMed     Abstract available


  278. ERQOU S, Adler AI, Challa AA, Fonarow GC, et al
    Insulin Resistance and Incident Heart Failure: A Meta-Analysis.
    Eur J Heart Fail. 2022 May 3. doi: 10.1002/ejhf.2531.
    PubMed    


  279. TOMASONI D, Adamo M, Metra M
    May 2022 at a glance. Focus on treatment: from epidemiologic data to randomized trials and new devices.
    Eur J Heart Fail. 2022;24:735-737.
    PubMed    


  280. COATS AJS
    What's all the fuss about a new guideline?
    Eur J Heart Fail. 2022;24:743-745.
    PubMed    


  281. SORAJJA P, Cavalcante J, Bapat V
    Setting expectations for transcatheter mitral valve replacement in the real world.
    Eur J Heart Fail. 2022;24:908-909.
    PubMed    


  282. FRERKER C, Karam N, Hahn RT, Thiele H, et al
    New ESC/EACTS guideline recommendations for the treatment of secondary mitral regurgitation: reflections on the evidence.
    Eur J Heart Fail. 2022;24:746-749.
    PubMed    


  283. REDDY YNV
    Using the ejection fraction to guide medical therapy: a necessary but imperfect first step.
    Eur J Heart Fail. 2022;24:779-781.
    PubMed    


  284. BEN ALI W, Ludwig S, Duncan A, Weimann J, et al
    Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI registry.
    Eur J Heart Fail. 2022;24:887-898.
    PubMed     Abstract available


  285. ROSANO GMC, Celant S, Olimpieri PP, Colatrella A, et al
    Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy.
    Eur J Heart Fail. 2022;24:855-860.
    PubMed     Abstract available


  286. BUTLER J, Spertus JA, Bamber L, Khan MS, et al
    Defining changes in physical limitation from the patient perspective: insights from the VITALITY-HFpEF randomized trial.
    Eur J Heart Fail. 2022;24:843-850.
    PubMed     Abstract available


  287. WILD MG, Kreidel F, Hell MM, Praz F, et al
    Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience.
    Eur J Heart Fail. 2022;24:899-907.
    PubMed     Abstract available


    April 2022
  288. AIMO A, Vergaro G, Gonzalez A, Barison A, et al
    Cardiac Remodelling Part 2: Clinical, Imaging and Laboratory Findings A review from the Biomarkers Working Group of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2022 Apr 30. doi: 10.1002/ejhf.2522.
    PubMed     Abstract available


  289. CARTER S, Hendren NS, Grodin JL
    Sodium-glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?
    Eur J Heart Fail. 2022 Apr 29. doi: 10.1002/ejhf.2516.
    PubMed    


  290. REZA N, Butler J
    Assessing Health Status After Discharge for Decompensated Heart Failure: A Patient-Centered Priority.
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2521.
    PubMed    


  291. BORIANI G, Imberti JF, Vitolo M
    Dronedarone in the treatment of atrial fibrillation with concomitant heart failure and preserved or mildly reduced ejection fraction: closer to Ithaca after a long Odyssey?
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2519.
    PubMed    


  292. PELLICORI P, Cleland JG
    Heart failure: age is no excuse for complacency.
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2517.
    PubMed    


  293. CANNATA A, Bromage DI, McDonagh TA
    COVID and heart failure: the dark side of the moon.
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2518.
    PubMed    


  294. KALOGEROPOULOS AP, Tam E
    Intravenous iron in heart failure with reduced ejection fraction: just about right.
    Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2520.
    PubMed    


  295. JIN X, Hung CL, Tay WT, Soon D, et al
    Epicardial Adipose Tissue related to Left Atrial and Ventricular Function in Heart Failure with Preserved (HFpEF) versus Reduced and Mildly Reduced Ejection Fraction (HFrEF/HFmrEF).
    Eur J Heart Fail. 2022 Apr 27. doi: 10.1002/ejhf.2513.
    PubMed     Abstract available


  296. XIE C
    Could angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitor be used in heart failure patients with atrial fibrillation and low blood pressure?
    Eur J Heart Fail. 2022 Apr 27. doi: 10.1002/ejhf.2515.
    PubMed    


  297. EMDIN M, Aimo A, Castiglione V
    Is Targeting Cyclic Guanosine Monophosphate by Vericiguat Effective to Treat Ischaemic Heart Failure with Reduced Ejection Fraction? Yes, It Is.
    Eur J Heart Fail. 2022 Apr 21. doi: 10.1002/ejhf.2511.
    PubMed    


  298. STRAW S, Gierula J, Witte KK
    Designing clinical trials in heart failure with preserved ejection fraction: quality over quantity?
    Eur J Heart Fail. 2022 Apr 21. doi: 10.1002/ejhf.2510.
    PubMed    


  299. MCNAUGHTON CD, McConnachie A, Cleland JG, Spertus JA, et al
    Quality of life assessed six months after hospitalisation for acute heart failure: An analysis from REPORT-HF (International Registry to assess mEdical Practice with lOngitudinal obseRvation for Treatment of Heart Failure).
    Eur J Heart Fail. 2022 Apr 16. doi: 10.1002/ejhf.2508.
    PubMed     Abstract available


  300. GIRERD N, Mewton N, Tartiere JM, Guijarro D, et al
    Practical outpatient management of worsening chronic heart failure.
    Eur J Heart Fail. 2022 Apr 13. doi: 10.1002/ejhf.2503.
    PubMed     Abstract available


  301. STEWART COATS AJ
    HeartFailureNews Figures of the Heart Failure Association: Professor Finn Gustafsson, Board Member, 2020-2022.
    Eur J Heart Fail. 2022 Apr 13. doi: 10.1002/ejhf.2502.
    PubMed    


  302. KALOGEROPOULOS AP, Butler J
    Uptitrating versus adding heart failure with reduced ejection fraction medications: bring more players to the game.
    Eur J Heart Fail. 2022 Apr 13. doi: 10.1002/ejhf.2507.
    PubMed    


  303. STEWART COATS AJ
    Figures of the Heart Failure Association: Doctor Amina Rakisheva, Board Member, 2020-2022.
    Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2499.
    PubMed    


  304. ALNUWAYSIR RIS, Grote Beverborg N, van der Meer P
    Fluctuating iron levels in heart failure: when and where to look at?
    Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2500.
    PubMed    


  305. VOORDES GHD, Heerspink HJL, Ter Maaten JM
    The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function.
    Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2501.
    PubMed    


  306. SINHA A, Yancy CW, Patel RB
    Tipping the scale toward a more accurate and equitable assessment of heart failure with reduced ejection fraction pharmacotherapy eligibility: a call to incorporate cystatin C in estimating glomerular filtration rate.
    Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2505.
    PubMed    


  307. RASTOGI T, Ho FK, Rossignol P, Merkling T, et al
    Comparing and contrasting risk factors for Heart failure in patients with and without history of myocardial infarction: Data from HOMAGE and the UK Biobank.
    Eur J Heart Fail. 2022 Apr 1. doi: 10.1002/ejhf.2495.
    PubMed     Abstract available


  308. TOMASONI D, Adamo M, Metra M
    April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2022;24:593-595.
    PubMed    


  309. CLELAND JGF, Butler J, Januzzi JL Jr, Pellicori P, et al
    Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice.
    Eur J Heart Fail. 2022;24:678-680.
    PubMed    


  310. GROTE BEVERBORG N
    The heart during iron deficiency: a non-rechargeable battery?
    Eur J Heart Fail. 2022;24:724-726.
    PubMed    


  311. TAVAZZI L, Maggioni AP, Rapezzi C, Ferrari R, et al
    Clinical trials: conventional or pragmatic?
    Eur J Heart Fail. 2022;24:596-599.
    PubMed    


  312. SIDHU K, Castrini AI, Parikh V, Reza N, et al
    The response to cardiac resynchronization therapy in LMNA cardiomyopathy.
    Eur J Heart Fail. 2022;24:685-693.
    PubMed     Abstract available


  313. CHIONCEL O, Adamo M, Bauersachs J
    Risk stratification in cardiogenic shock: from clinical utility to improving outcomes.
    Eur J Heart Fail. 2022;24:668-671.
    PubMed    


  314. MARINO PN, Zanaboni J
    Does left atrial deformation impact on symptoms and prognosis in functional mitral regurgitation patients with poor left ventricular function?
    Eur J Heart Fail. 2022;24:705-707.
    PubMed    


  315. HOLM H, Magnusson M, Jujic A, Bozec E, et al
    How to calculate ventricular-arterial coupling?
    Eur J Heart Fail. 2022;24:600-602.
    PubMed    


  316. HAVAKUK O, Topilsky Y
    The interplay between functional mitral regurgitation and left atrial function.
    Eur J Heart Fail. 2022;24:703-704.
    PubMed    


  317. IKONOMIDIS I, Lambadiari V, Mitrakou A, Kountouri A, et al
    Myocardial work and vascular dysfunction are partially improved at 12 months after COVID-19 infection.
    Eur J Heart Fail. 2022;24:727-729.
    PubMed    


  318. BEER BN, Jentzer JC, Weimann J, Dabboura S, et al
    Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause - the Cardiogenic Shock Score.
    Eur J Heart Fail. 2022;24:657-667.
    PubMed     Abstract available


    March 2022
  319. NIJHOLT KT, Westenbrink BD
    Reply to letter to the editor regarding the article 'Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?'
    Eur J Heart Fail. 2022 Mar 26. doi: 10.1002/ejhf.2494.
    PubMed    


  320. ANKER SD, Ponikowski P, Khan MS, Friede T, et al
    Responder analysis for improvement in six-minute walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
    Eur J Heart Fail. 2022 Mar 25. doi: 10.1002/ejhf.2491.
    PubMed     Abstract available



  321. Corrigendum to 'Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy' [Eur J Heart Fail 2021;23:854-871].
    Eur J Heart Fail. 2022 Mar 17. doi: 10.1002/ejhf.2474.
    PubMed    


  322. DEVORE AD, Hellkamp AS, Thomas L, Albert NM, et al
    The Association of Improvement in Left Ventricular Ejection Fraction with Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Data from CHAMP-HF.
    Eur J Heart Fail. 2022 Mar 15. doi: 10.1002/ejhf.2486.
    PubMed     Abstract available


  323. VADUGANATHAN M, Piccini JP, Camm AJ, Crijns HJGM, et al
    Dronedarone for the Treatment of Atrial Fibrillation with Concomitant Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Post-Hoc Analysis of the ATHENA Trial.
    Eur J Heart Fail. 2022 Mar 15. doi: 10.1002/ejhf.2487.
    PubMed     Abstract available


  324. KESHVANI N, Mehta A, Alger HM, Rutan C, et al
    Heart Failure Quality of Care and In-Hospital Outcomes During the COVID-19 Pandemic Findings from the Get With The Guidelines-Heart Failure Registry.
    Eur J Heart Fail. 2022 Mar 14. doi: 10.1002/ejhf.2484.
    PubMed     Abstract available


  325. BUTLER J, Khan MS, Friede T, Jankowska EA, et al
    Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency.
    Eur J Heart Fail. 2022 Mar 13. doi: 10.1002/ejhf.2478.
    PubMed     Abstract available


  326. FORREST IS, Rocheleau G, Bafna S, Argulian E, et al
    Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure.
    Eur J Heart Fail. 2022 Mar 12. doi: 10.1002/ejhf.2482.
    PubMed     Abstract available


  327. STOLFO D, Lund LH, Becher PM, Orsini N, et al
    Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata.
    Eur J Heart Fail. 2022 Mar 12. doi: 10.1002/ejhf.2483.
    PubMed     Abstract available



  328. Corrigendum to 'Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study
    Eur J Heart Fail. 2022 Mar 10. doi: 10.1002/ejhf.2473.
    PubMed    



  329. Corrigendum to 'Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry [Eur J Heart Fail 2021;23:1844-1854].
    Eur J Heart Fail. 2022 Mar 10. doi: 10.1002/ejhf.2472.
    PubMed    


  330. D'AMARIO D, Rodolico D, Rosano GM, Dahlstrom U, et al
    Association Between Dosing And Combination Use Of Medications And Outcomes In Heart Failure With Reduced Ejection Fraction: Data From The Swedish Heart Failure Registry.
    Eur J Heart Fail. 2022 Mar 8. doi: 10.1002/ejhf.2477.
    PubMed     Abstract available


  331. KONSTAM MA
    Autonomic Dysregulation in Diabetes: CAN We Prevent Heart Failure?
    Eur J Heart Fail. 2022 Mar 4. doi: 10.1002/ejhf.2476.
    PubMed    


  332. SALDARRIAGA C, Atar D, Stebbins A, Lewis BS, et al
    Vericiguat in Patients with Coronary Artery Disease and Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2468.
    PubMed     Abstract available


  333. KHAN MS, Shahid I, Fonarow GC, Greene SJ, et al
    Classifying Heart Failure Based on Ejection Fraction: Imperfect but Enduring.
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2470.
    PubMed    


  334. FILIPPATOS G, Pitt B, Agarwal R, Farmakis D, et al
    Finerenone in patients with CKD and T2D with and without heart failure: A prespecified subgroup analysis of the FIDELIO-DKD trial.
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2469.
    PubMed     Abstract available


  335. MULLENS W, Martens P, Testani JM, Tang WHW, et al
    Renal effects of guideline directed medical therapies in heart failure - a consensus document from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2471.
    PubMed    


  336. KOKHAN E, Kiyakbaev G, Medovchshikov V
    Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article "Early benefit with empagliflozin in heart failure with preserved ejecti
    Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2466.
    PubMed    


  337. ANDRIOPOULOU M, Dimaki N, Kallistratos MS, Chamodraka E, et al
    Skeletal muscle alterations and exercise intolerance in heart failure with preserved ejection fraction patients: ultrasonography assessment of diaphragm and quadriceps.
    Eur J Heart Fail. 2022 Mar 1. doi: 10.1002/ejhf.2462.
    PubMed    


  338. TOMASONI D, Adamo M, Metra M
    March 2022 at a glance: focus on medical therapy, prevention and comorbidities.
    Eur J Heart Fail. 2022;24:403-405.
    PubMed    


  339. DAUW J, Mullens W, Girerd N
    The fastest way to the heart is through the veins: towards a better understanding of congestion.
    Eur J Heart Fail. 2022;24:463-465.
    PubMed    


  340. KOEHLER F, Schulz M
    The AMULET menage a trois: nurse, telemedicine support, and remote cardiologist.
    Eur J Heart Fail. 2022;24:578-580.
    PubMed    


  341. DE SOUSA C, Pinto FJ
    Dapagliflozin post-transcatheter aortic valve implantation: the need for further evidence.
    Eur J Heart Fail. 2022;24:589-590.
    PubMed    


  342. DONAL E, Sade LE, Thomas L
    Left atrial function: the HbA1c for the cardiologist and even more.
    Eur J Heart Fail. 2022;24:494-496.
    PubMed    


  343. CURTAIN JP, Jackson AM, Shen L, Jhund PS, et al
    Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.
    Eur J Heart Fail. 2022;24:551-561.
    PubMed     Abstract available


  344. RUSSO G, Taramasso M, Pedicino D, Gennari M, et al
    Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?
    Eur J Heart Fail. 2022;24:442-454.
    PubMed     Abstract available


  345. IVEY-MIRANDA JB, Wetterling F, Gaul R, Sheridan S, et al
    Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone.
    Eur J Heart Fail. 2022;24:455-462.
    PubMed     Abstract available


  346. AMAT-SANTOS IJ, Sanchez-Luna JP, Abu-Assi E, Melendo-Viu M, et al
    Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.
    Eur J Heart Fail. 2022;24:581-588.
    PubMed     Abstract available


    February 2022
  347. BHATT AS, Fonarow GC, Greene SJ
    Prioritizing Prevention of De Novo and Worsening Chronic Heart Failure.
    Eur J Heart Fail. 2022 Feb 25. doi: 10.1002/ejhf.2464.
    PubMed    


  348. KAMBIC T, Piepoli MF, Lainscak M
    Exercise intolerance in heart failure: beyond mitochondrial dysfunction.
    Eur J Heart Fail. 2022 Feb 25. doi: 10.1002/ejhf.2461.
    PubMed    


  349. FERREIRA JP, Verdonschot JAJ, Girerd N, Bozec E, et al
    Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.
    Eur J Heart Fail. 2022 Feb 23. doi: 10.1002/ejhf.2455.
    PubMed     Abstract available


  350. BUTT JH, Adamson C, Docherty KF, Vaduganathan M, et al
    Eligibility for Pharmacological Therapies in Heart Failure with Reduced Ejection Fraction: Implications of the New CKD-EPI Creatinine Equation for Estimating Glomerular Filtration Rate.
    Eur J Heart Fail. 2022 Feb 23. doi: 10.1002/ejhf.2460.
    PubMed     Abstract available


  351. PAPALIA F, Jouhra F, Amin-Youssef G, Shah AM, et al
    Cardiac Energetics in Patients with Chronic Heart Failure and Iron Deficiency: An in-vivo 31P Magnetic Resonance Study.
    Eur J Heart Fail. 2022 Feb 23. doi: 10.1002/ejhf.2454.
    PubMed     Abstract available


  352. FERREIRA JP, Packer M, Butler J, Zannad F, et al
    Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure.
    Eur J Heart Fail. 2022 Feb 22. doi: 10.1002/ejhf.2457.
    PubMed     Abstract available


  353. ROSSIGNOL P, Pitt B
    Time to Shift our Focus from the Treatment to the Prevention of Heart Failure with a Mineralocorticoid Receptor Antagonist (MRA)?
    Eur J Heart Fail. 2022 Feb 21. doi: 10.1002/ejhf.2459.
    PubMed    


  354. IKONOMIDIS I, Vlastos D
    Corrigendum to 'The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Periph
    Eur J Heart Fail. 2022 Feb 9. doi: 10.1002/ejhf.2452.
    PubMed    


  355. PEIKERT A, Vaduganathan M, McCausland F, Claggett BL, et al
    Effects of Sacubitril/Valsartan Versus Valsartan on Renal Function in Patients with and without Diabetes and Heart Failure with Preserved Ejection Fraction: Insights From PARAGON-HF.
    Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2450.
    PubMed     Abstract available


  356. DEO SV, Reddy YN, Zakeri R, Karnib M, et al
    Revascularization in Ischemic Heart Failure with Preserved Ejection Fraction: A Nationwide Cohort Study.
    Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2446.
    PubMed    


  357. MOHAMED MO
    Prevention is better than cure: modifiable risk factors for heart failure better understood.
    Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2448.
    PubMed    


  358. KONDO T, Jhund PS, McMurray JJV
    Drug therapy for heart failure with reduced ejection fraction: what is the 'right' dose?
    Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2447.
    PubMed     Abstract available


  359. VARSHNEY AS, Singh JP, Vaduganathan M
    A Heart Team Approach to Contemporary Device Decision-Making in Heart Failure.
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2445.
    PubMed    


  360. PITT B, Epstein M
    A Promise Unfulfilled : The use of Mineralocorticoid Receptor Antagonists ( MRAs ) in patients with Heart Failure and a Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2441.
    PubMed    


  361. ARITA VA, Van Veldhuisen DJ, Rienstra M
    Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation.
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2443.
    PubMed    


  362. EL-BATTRAWY I, Akin I
    Impact of sacubitril/valsartan on cardiac arrest event rate. Letter regarding the article 'Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baselin
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2444.
    PubMed    


  363. OMAR M, Jensen MD, Borlaug BA
    Diabesity and heart failure with preserved ejection fraction: the picture is getting clearer.
    Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2440.
    PubMed    



  364. HFA Winter Meeting on Translational Heart Failure Research 27-28 January 2022.
    Eur J Heart Fail. 2022;24 Suppl 1:3-12.
    PubMed    


  365. TOMASONI D, Adamo M, Metra M
    February 2022 at a glance: focus on pathophysiology and acute heart failure.
    Eur J Heart Fail. 2022;24:243-244.
    PubMed    


  366. TREVISAN M, Fu EL, Carrero JJ
    Reply to the letter regarding the article 'Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care'.
    Eur J Heart Fail. 2022;24:399-400.
    PubMed    


  367. WARRAICH HJ, Nohria A
    Is worsening renal function relevant without clinical context?
    Eur J Heart Fail. 2022;24:375-377.
    PubMed    


  368. FACILE A, Mewton N, Nguon M, Durand de Gevigney G, et al
    Primary endpoint adjudication: comparison between the expert committee and the regulatory MedDRA(R) coding in the MITRA-FR study.
    Eur J Heart Fail. 2022;24:396-398.
    PubMed    


  369. ALEXANDROU ME, Sarafidis PA
    Letter regarding the article 'Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care'.
    Eur J Heart Fail. 2022;24:399.
    PubMed    


  370. OBOKATA M, Reddy YNV, Melenovsky V, Sorimachi H, et al
    Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity.
    Eur J Heart Fail. 2022;24:353-361.
    PubMed     Abstract available


    January 2022
  371. PABON MA, Cunningham JW, Claggett BL, Packer M, et al
    Natriuretic Peptide-Based Inclusion Criteria in Heart Failure with Preserved Ejection Fraction Clinical Trials: Insights from PARAGON-HF.
    Eur J Heart Fail. 2022 Jan 26. doi: 10.1002/ejhf.2439.
    PubMed     Abstract available


  372. KAZE AD, Yuyun MF, Erqou S, Fonarow GC, et al
    Cardiac Autonomic Neuropathy and Risk of Incident Heart Failure Among Adults with Type 2 Diabetes.
    Eur J Heart Fail. 2022 Jan 22. doi: 10.1002/ejhf.2432.
    PubMed     Abstract available


  373. TROMP J, Beusekamp JC, Ouwerkerk W, van der Meer P, et al
    Regional Differences in Precipitating Factors of Hospitalization for Acute Heart Failure: Insights from the REPORT-HF Registry.
    Eur J Heart Fail. 2022 Jan 22. doi: 10.1002/ejhf.2431.
    PubMed     Abstract available


  374. CHANDRAMOULI C, Ting TW, Tromp J, Agarwal A, et al
    Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction.
    Eur J Heart Fail. 2022 Jan 21. doi: 10.1002/ejhf.2435.
    PubMed     Abstract available


  375. MULLENS W, Coats A, Seferovic P, Metra M, et al
    Education and Certification on Heart Failure of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2022 Jan 11. doi: 10.1002/ejhf.2430.
    PubMed     Abstract available


  376. POTTER E, Stephenson G, Harris J, Wright L, et al
    Screening-Guided Spironolactone Treatment of Subclinical Left Ventricular Dysfunction for Heart Failure Prevention in At-risk Patients.
    Eur J Heart Fail. 2022 Jan 11. doi: 10.1002/ejhf.2428.
    PubMed     Abstract available


  377. MALAGOLI A, Rossi L, Zanni A, Sticozzi C, et al
    Quantified mitral regurgitation and left atrial function in heart failure with reduced ejection fraction: interplay and outcome implications.
    Eur J Heart Fail. 2022 Jan 11. doi: 10.1002/ejhf.2429.
    PubMed     Abstract available


  378. MC CAUSLAND FR, Lefkowitz MP, Claggett B, Packer M, et al
    Angiotensin-Neprilysin Inhibition and Renal Outcomes Across the Spectrum of Ejection Fraction in Heart Failure.
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2421.
    PubMed     Abstract available


  379. PATEL RB, Shah SJ, Inciardi RM
    Collagen Homeostasis of the Left Atrium: An Emerging Treatment Target to Prevent Heart Failure?
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2422.
    PubMed    


  380. MADIAS JE
    Pathophysiology and therapy of Takotsubo syndrome. Letter regarding the article 'Pathophysiology of Takotsubo syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Gro
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2413.
    PubMed    


  381. DOUMAS M, Patoulias D, Papadopoulos C
    Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in patients with heart failure? Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, m
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2412.
    PubMed    


  382. CEELEN D, Voors AA, Tromp J, van Veldhuisen DJ, et al
    Pathophysiological pathways related to high plasma GDF-15 concentrations in patients with heart failure.
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2424.
    PubMed     Abstract available


  383. BUTLER J, Siddiqi TJ, Filippatos G, Ferreira JP, et al
    Early Benefit with Empagliflozin in Heart Failure with Preserved Ejection Fraction Insights from the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2420.
    PubMed     Abstract available


  384. DE BIASE N, Del Punta L, Pugliese NR
    Reply: Epicardial adipose tissue: does it mediate the cardio-protective effects of SGLT-2 inhibitors in subjects with heart failure?
    Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2423.
    PubMed    


  385. PIEPOLI MF, Adamo M, Barison A, Bestetti RB, et al
    Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology.
    Eur J Heart Fail. 2022;24:143-168.
    PubMed     Abstract available


  386. TOMASONI D, Adamo M, Metra M
    January 2022 at a glance: time for the new ESC guidelines on heart failure.
    Eur J Heart Fail. 2022;24:1-3.
    PubMed    


  387. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
    2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contri
    Eur J Heart Fail. 2022;24:4-131.
    PubMed     Abstract available


  388. AKTAA S, Polovina M, Rosano G, Abdin A, et al
    European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society o
    Eur J Heart Fail. 2022;24:132-142.
    PubMed     Abstract available


  389. ROSENKRANZ S, Channick R, Chin KM, Jenner B, et al
    The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
    Eur J Heart Fail. 2022;24:205-214.
    PubMed     Abstract available


    December 2021
  390. ZAHIR D, Bonde A, Madelaire C, Malmborg M, et al
    Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: A nationwide study in Denmark from 2003-2017.
    Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2418.
    PubMed     Abstract available


  391. BANERJEE A, Pasea L, Chung SC, Direk K, et al
    A population-based study of 92 clinically recognised risk factors for heart failure: co-occurrence, prognosis and preventive potential.
    Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2417.
    PubMed     Abstract available


  392. DE BOER RA, Heymans S, Backs J, Carrier L, et al
    Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society o
    Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2414.
    PubMed     Abstract available


  393. MEEMS LMG, van Veldhuisen DJ, de Boer RA
    Underestimation of congestion in very obese heart failure with preserved ejection fraction patients: EAT your heart out...?!
    Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2415.
    PubMed    


  394. KAPLON-CIESLICKA A, Benson L, Chioncel O, Crespo-Leiro MG, et al
    A comprehensive characterization of acute heart failure with preserved vs. mildly reduced vs. reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2021 Dec 27. doi: 10.1002/ejhf.2408.
    PubMed     Abstract available


  395. BAYES-GENIS A, Nunez J, Lupon J
    Dysglycemia and High Natriuretic Peptides: The Prelude to Heart Failure.
    Eur J Heart Fail. 2021 Dec 26. doi: 10.1002/ejhf.2410.
    PubMed    


  396. NIJHOLT KT, Sanchez-Aguilera PI, Voorrips SN, de Boer RA, et al
    Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?
    Eur J Heart Fail. 2021 Dec 26. doi: 10.1002/ejhf.2407.
    PubMed     Abstract available


  397. FERREIRA JP, Anker SD, Butler J, Filippatos G, et al
    Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced.
    Eur J Heart Fail. 2021 Dec 26. doi: 10.1002/ejhf.2409.
    PubMed     Abstract available


  398. AL-MUBARAK AA, Beverborg NG, Suthahar N, Gansevoort RT, et al
    High selenium levels associate with reduced risk of mortality and new onset heart failure: data from PREVEND.
    Eur J Heart Fail. 2021 Dec 20. doi: 10.1002/ejhf.2405.
    PubMed     Abstract available



  399. Corrigendum to 'Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials' [Eur J Heart Fail 2020;11:2160-2171].
    Eur J Heart Fail. 2021 Dec 20. doi: 10.1002/ejhf.2404.
    PubMed    


  400. ANDERSEN DM, Sengelov M, Olsen FJ, Marott JL, et al
    Measures of Left Atrial Function Predicts Incident Heart Failure in a Low Risk General Population: The Copenhagen City Heart Study.
    Eur J Heart Fail. 2021 Dec 20. doi: 10.1002/ejhf.2406.
    PubMed     Abstract available


  401. JACKSON AM, Rorth R, Liu J, Kristensen SL, et al
    Diabetes and prediabetes in patients with heart failure and preserved ejection fraction.
    Eur J Heart Fail. 2021 Dec 17. doi: 10.1002/ejhf.2403.
    PubMed     Abstract available


  402. WEIR RA, Clements S, Steedman T, Dargie HJ, et al
    Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10 year follow-up of the Eplerenone Remodeling in Myocardial Infarction without Heart Failure trial.
    Eur J Heart Fail. 2021 Dec 14. doi: 10.1002/ejhf.2402.
    PubMed     Abstract available


  403. OMEROVIC E, Citro R, Bossone E, Redfors B, et al
    Pathophysiology of Takotsubo Syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology - Part 1: Overview and the central role
    Eur J Heart Fail. 2021 Dec 14. doi: 10.1002/ejhf.2400.
    PubMed     Abstract available


  404. TOMASONI D, Fonarow GC, Adamo M, Anker SD, et al
    Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2021 Dec 10. doi: 10.1002/ejhf.2397.
    PubMed     Abstract available


  405. PAGNESI M, Butler J, Metra M
    Ejection fraction in heart failure: just become Emperor's new clothes?
    Eur J Heart Fail. 2021 Dec 10. doi: 10.1002/ejhf.2399.
    PubMed    


  406. TOMASONI D, Adamo M, Metra M
    December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models.
    Eur J Heart Fail. 2021;23:1993-1994.
    PubMed    


  407. VAN BERGEIJK KH, Voors AA, Wykrzykowska JJ
    Prime time for machine learning to predict clinical outcomes in valvular heart disease?
    Eur J Heart Fail. 2021;23:2033-2034.
    PubMed    


  408. SINAGRA G, Porcari A, Fabris E, Merlo M, et al
    Standardizing the role of endomyocardial biopsy in current clinical practice worldwide.
    Eur J Heart Fail. 2021;23:1995-1998.
    PubMed    


  409. VIDULA MK, Orlenko A, Zhao L, Salvador L, et al
    Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis.
    Eur J Heart Fail. 2021;23:2021-2032.
    PubMed     Abstract available


  410. STRACHINARU M, Nijveldt R, Vernooy K
    Arrhythmic risk management after acute myocarditis: never too early, only too late.
    Eur J Heart Fail. 2021;23:2055-2057.
    PubMed    


  411. HALLIDAY BP, de Marvao A, Thilaganathan B
    Peripartum cardiomyopathy and pre-eclampsia: two tips of the same iceberg.
    Eur J Heart Fail. 2021;23:2070-2072.
    PubMed    


  412. GENTILE P, Merlo M, Peretto G, Ammirati E, et al
    Post-discharge arrhythmic risk stratification of patients with acute myocarditis and life-threatening ventricular tachyarrhythmias.
    Eur J Heart Fail. 2021;23:2045-2054.
    PubMed     Abstract available


  413. SUZUKI K, Claggett B, Minamisawa M, Packer M, et al
    Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial.
    Eur J Heart Fail. 2021;23:2085-2090.
    PubMed     Abstract available


  414. JACKSON AM, Petrie MC, Frogoudaki A, Laroche C, et al
    Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry.
    Eur J Heart Fail. 2021;23:2058-2069.
    PubMed     Abstract available


    November 2021
  415. RAVASSA S, Lopez B, Ferreira JP, Girerd N, et al
    Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling.
    Eur J Heart Fail. 2021 Nov 28. doi: 10.1002/ejhf.2394.
    PubMed     Abstract available



  416. Corrigendum to 'High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality' [Eur J Heart Fail 2021;23:919-932].
    Eur J Heart Fail. 2021 Nov 24. doi: 10.1002/ejhf.2383.
    PubMed    


  417. FAUCHIER L, Bisson A, Lip GYH
    Age, sex and clinical outcomes with digoxin vs beta-blocker in permanent atrial fibrillation with heart failure.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2389.
    PubMed    


  418. ALNUWAYSIR RIS, Grote Beverborg N, Hoes MF, Markousis-Mavrogenis G, et al
    Additional Burden of Iron Deficiency in Heart Failure Patients beyond the Cardio-Renal-Anaemia Syndrome: Findings from the BIOSTAT-CHF Study.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2393.
    PubMed     Abstract available


  419. CULIC V
    Digoxin and beta-blockers in patients with heart failure.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2392.
    PubMed    


  420. NAITO R, Kasai T
    Bereavement of a child as a risk of heart failure.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2388.
    PubMed    


  421. MADIAS JE
    Pathophysiology of Takotsubo syndrome: still a puzzle. Letter regarding the article 'Pathophysiology of Takotsubo syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2390.
    PubMed    


  422. MAEDER MT
    Selexipag and the Pulmonary Hypertension Continuum.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2387.
    PubMed    


  423. BUTLER J, Anker SD, Siddiqi TJ, Coats AJS, et al
    Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Eur J Heart Fail. 2021 Nov 20. doi: 10.1002/ejhf.2386.
    PubMed     Abstract available


  424. TER MAATEN JM, Beldhuis IE, van der Meer P, Krikken JA, et al
    Natriuresis guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based Treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial.
    Eur J Heart Fail. 2021 Nov 17. doi: 10.1002/ejhf.2385.
    PubMed     Abstract available


  425. EMMENS JE, Ter Maaten JM, Matsue Y, Figarska SM, et al
    Worsening renal function in acute heart failure in the context of diuretic response.
    Eur J Heart Fail. 2021 Nov 17. doi: 10.1002/ejhf.2384.
    PubMed     Abstract available


  426. GREENE SJ, Butler J, Fonarow GC
    In-hospital Initiation of Quadruple Medical Therapy for Heart Failure: Making the Post-Discharge Vulnerable Phase Far Less Vulnerable.
    Eur J Heart Fail. 2021 Nov 14. doi: 10.1002/ejhf.2382.
    PubMed    


  427. BUTT JH, Docherty KF, Jhund PS, De Boer RA, et al
    Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: Insights from DAPA-HF.
    Eur J Heart Fail. 2021 Nov 11. doi: 10.1002/ejhf.2381.
    PubMed     Abstract available


  428. SEFEROVIC PM, Polovina M, Adlbrecht C, BElohlavek J, et al
    Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical treatment in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2021 Nov 9. doi: 10.1002/ejhf.2378.
    PubMed     Abstract available


  429. FERREIRA JP, Liu J, Claggett BL, Vardeny O, et al
    Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT.
    Eur J Heart Fail. 2021 Nov 9. doi: 10.1002/ejhf.2376.
    PubMed     Abstract available


  430. SEGAR MW, Khan MS, Patel KV, Vaduganathan M, et al
    Incorporation of Natriuretic Peptides with Clinical Risk-scores to Predict Heart Failure Among Individuals with Dysglycemia.
    Eur J Heart Fail. 2021 Nov 3. doi: 10.1002/ejhf.2375.
    PubMed     Abstract available


  431. COHEN-SOLAL A, Beauvais F
    New treatments for heart failure and exercise capacity.
    Eur J Heart Fail. 2021 Nov 1. doi: 10.1002/ejhf.2374.
    PubMed    


  432. GHANTOUS E, Topilsky Y
    Recovery of cardiac function following COVID-19.
    Eur J Heart Fail. 2021;23:1913-1915.
    PubMed    


  433. LASSEN MCH, Skaarup KG, Lind JN, Alhakak AS, et al
    Recovery of cardiac function following COVID-19 - ECHOVID-19: a prospective longitudinal cohort study.
    Eur J Heart Fail. 2021;23:1903-1912.
    PubMed     Abstract available


  434. LAMBADIARI V, Mitrakou A, Kountouri A, Thymis J, et al
    Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection.
    Eur J Heart Fail. 2021;23:1916-1926.
    PubMed     Abstract available


  435. DERDA AA, Garg A, Bar C, Thum T, et al
    Reply to 'COVID-19 severity, miR-21 targets, and common human genetic variation'.
    Eur J Heart Fail. 2021;23:1987-1988.
    PubMed    


  436. DINGSDAG SA, Clay OK, Quintero GA
    COVID-19 severity, miR-21 targets, and common human genetic variation. Letter regarding the article 'Circulating cardiovascular microRNAs in critically ill COVID-19 patients'.
    Eur J Heart Fail. 2021;23:1986-1987.
    PubMed    


  437. TOMASONI D, Adamo M, Metra M
    November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices.
    Eur J Heart Fail. 2021;23:1803-1805.
    PubMed    


  438. WITTE KK, Goldberg SL, Kaye D, Starling R, et al
    Reply to 'Benefits of transvenous mitral annuloplasty in heart failure with lower degrees of functional mitral regurgitation'.
    Eur J Heart Fail. 2021;23:1985-1986.
    PubMed    


  439. SEFEROVIC PM
    Reply to "Endomyocardial biopsy in the hands of the electrophysiologist: the 'one-stop shop' for arrhythmic non-ischaemic cardiomyopathy".
    Eur J Heart Fail. 2021;23:1984.
    PubMed    


  440. COTTER G, Davison B, Metra M, Sliwa K, et al
    Amended STRONG-HF study design.
    Eur J Heart Fail. 2021;23:1981-1982.
    PubMed    


  441. CHIONCEL O, Metra M
    Cardiogenic shock centres for optimal care coordination and improving outcomes in cardiogenic shock.
    Eur J Heart Fail. 2021;23:1938-1941.
    PubMed    


  442. BARAN DA
    A deceptively simple problem: the case of cardiogenic shock.
    Eur J Heart Fail. 2021;23:1952-1954.
    PubMed    


  443. WITTE KK, Kaye DM, Lipiecki J, Siminiak T, et al
    Treating symptoms and reversing remodelling: clinical and echocardiographic 1-year outcomes with percutaneous mitral annuloplasty for mild to moderate secondary mitral regurgitation.
    Eur J Heart Fail. 2021;23:1971-1978.
    PubMed     Abstract available


  444. SCHRAGE B, Beer BN, Savarese G, Dabboura S, et al
    Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials.
    Eur J Heart Fail. 2021;23:1942-1951.
    PubMed     Abstract available


  445. LU DY, Adelsheimer A, Chan K, Yeo I, et al
    Impact of hospital transfer to hubs on outcomes of cardiogenic shock in the real world.
    Eur J Heart Fail. 2021;23:1927-1937.
    PubMed     Abstract available


    October 2021
  446. FRASER AG, Szymanski P
    Heart valve disease, left ventricular hypertrophy, and heart failure: a lifelong relationship and continuing clinical responsibility.
    Eur J Heart Fail. 2021 Oct 24. doi: 10.1002/ejhf.2373.
    PubMed    


  447. WEI D, Li J, Janszky I, Chen H, et al
    Death of a child and the risk of heart failure: a population-based cohort study from Denmark and Sweden.
    Eur J Heart Fail. 2021 Oct 24. doi: 10.1002/ejhf.2372.
    PubMed     Abstract available


  448. OMEROVIC E, Citro R, Bossone E, Redfors B, et al
    Pathophysiology of Takotsubo Syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology - Part 2: vascular pathophysiology, gend
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2368.
    PubMed     Abstract available


  449. MINANA G, Bayes-Genis A, Nunez J
    Iron deficiency testing and treatment in heart failure: the eyes are useless when the mind is blind.
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2365.
    PubMed    


  450. MARTENS P
    Detecting Subclinical Congestion in Stage A/B pre-Heart Failure - A glimpse into the future?
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2366.
    PubMed    


  451. TROMP J, Packer M, Lam C
    The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal.
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2363.
    PubMed    


  452. ADAMO M, Metra M
    Can mild to moderate secondary mitral regurgitation be a therapeutic target for symptomatic patients with heart failure with reduced ejection fraction?
    Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2362.
    PubMed    


  453. CUTHBERT JJ, Pellicori P, Flockton R, Kallvikbacka-Bennett A, et al
    The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure.
    Eur J Heart Fail. 2021 Oct 10. doi: 10.1002/ejhf.2353.
    PubMed     Abstract available


  454. LAUDER L, Pereira TV, Degenhardt MC, Ewen S, et al
    Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: A systematic review and meta-analysis.
    Eur J Heart Fail. 2021 Oct 10. doi: 10.1002/ejhf.2360.
    PubMed     Abstract available


  455. LOGEART D, Berthelot E, Bihry N, Eschalier R, et al
    Early and short-term intensive management after discharge for patients hospitalized with acute heart failure, a randomized study (ECAD-HF).
    Eur J Heart Fail. 2021 Oct 9. doi: 10.1002/ejhf.2357.
    PubMed     Abstract available


  456. KRZESINSKI P, Jankowska EA, Siebert J, Galas A, et al
    Effects of an outpatient intervention comprising nurse-led non-invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (AMULET Study): a randomised controlled trial.
    Eur J Heart Fail. 2021 Oct 6. doi: 10.1002/ejhf.2358.
    PubMed     Abstract available


  457. ROSANO G, Jankowska EA, Ray R, Metra M, et al
    COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2021 Oct 6. doi: 10.1002/ejhf.2356.
    PubMed     Abstract available



  458. Corrigendum to 'Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials' [Eur J Heart Fail 2016;18:684-692].
    Eur J Heart Fail. 2021 Oct 4. doi: 10.1002/ejhf.2354.
    PubMed    


  459. TOMASONI D, Adamo M, Metra M
    October 2021 at a glance: focus on imaging, biomarkers and comorbidities.
    Eur J Heart Fail. 2021;23:1569-1571.
    PubMed    


  460. PACKER M, Zannad F, Butler J, Filippatos G, et al
    Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial.
    Eur J Heart Fail. 2021;23:1798-1799.
    PubMed    


  461. BEN GAL T, Ben Avraham B, Milicic D, Crespo-Leiro MG, et al
    Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary.
    Eur J Heart Fail. 2021;23:1597-1609.
    PubMed     Abstract available


  462. GUAZZI M, Adamo M
    Cardiac output in severe tricuspid regurgitation: when more is less.
    Eur J Heart Fail. 2021;23:1795-1797.
    PubMed    


  463. CAMPOCHIARO C, De Luca G, Dagna L
    Cardiac immune-related adverse events: an immune-cardio-oncology puzzle.
    Eur J Heart Fail. 2021;23:1748-1749.
    PubMed    


  464. USMAN MS, Pitt B, Butler J
    Target trial emulations: bridging the gap between clinical trial and real-world data.
    Eur J Heart Fail. 2021;23:1708-1711.
    PubMed    


  465. ENRIQUEZ-SARANO M, Benfari G, Messika-Zeitoun D, Grigioni F, et al
    Functional mitral regurgitation: a proportionate or disproportionate focus of attention?
    Eur J Heart Fail. 2021;23:1759-1762.
    PubMed    


  466. PATTERSON T, Gregson J, Erglis A, Joseph J, et al
    Two-year outcomes from the MitrAl ValvE RepaIr Clinical (MAVERIC) trial: a novel percutaneous treatment of functional mitral regurgitation.
    Eur J Heart Fail. 2021;23:1775-1783.
    PubMed     Abstract available


  467. CAIFFA T, De Luca A, Biagini E, Lupi L, et al
    Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation.
    Eur J Heart Fail. 2021;23:1765-1774.
    PubMed     Abstract available


  468. UNTERHUBER M, Kresoja KP, Besler C, Rommel KP, et al
    Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosis.
    Eur J Heart Fail. 2021;23:1784-1794.
    PubMed     Abstract available


  469. RIZZO S, De Gaspari M, Basso C
    Immune checkpoint inhibitor myocarditis: a call for standardized histopathologic criteria.
    Eur J Heart Fail. 2021;23:1736-1738.
    PubMed    


  470. ZENG DX, Jiang JH
    Letter regarding the article 'Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure'.
    Eur J Heart Fail. 2021;23:1800.
    PubMed    


  471. TREVISAN M, Fu EL, Xu Y, Savarese G, et al
    Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care.
    Eur J Heart Fail. 2021;23:1698-1707.
    PubMed     Abstract available


  472. RUBIO-INFANTE N, Ramirez-Flores YA, Castillo EC, Lozano O, et al
    Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.
    Eur J Heart Fail. 2021;23:1739-1747.
    PubMed     Abstract available


  473. PALASKAS NL, Segura A, Lelenwa L, Siddiqui BA, et al
    Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy.
    Eur J Heart Fail. 2021;23:1725-1735.
    PubMed     Abstract available


    September 2021
  474. HALLE M, Schobel C, Winzer EB, Bernhardt P, et al
    A randomized clinical trial on the short-term effects of 12 weeks sacubitril/valsartan versus enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: Results from the ACTIVITY-HF study.
    Eur J Heart Fail. 2021 Sep 30. doi: 10.1002/ejhf.2355.
    PubMed     Abstract available


  475. CODINA P, Lupon J, Borrellas A, Spitaleri G, et al
    Head-to-head comparison of contemporary heart failure risk scores.
    Eur J Heart Fail. 2021 Sep 24. doi: 10.1002/ejhf.2352.
    PubMed     Abstract available


  476. YEOH SE, Dewan P, Serenelli M, Ferreira JP, et al
    Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES.
    Eur J Heart Fail. 2021 Sep 18. doi: 10.1002/ejhf.2350.
    PubMed     Abstract available



  477. Corrigendum to 'Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction' [Eur J Heart Fail 2021; 23, 983-991.].
    Eur J Heart Fail. 2021 Sep 12. doi: 10.1002/ejhf.2341.
    PubMed    


  478. KAMMERLANDER AA, Nitsche C, Dona C, Koschutnik M, et al
    Heart Failure with Preserved Ejection Fraction after Left-sided Valve Surgery: Prevalent and Relevant.
    Eur J Heart Fail. 2021 Sep 10. doi: 10.1002/ejhf.2345.
    PubMed     Abstract available


  479. COMPAGNUCCI P, Dello Russo A, Casella M
    Endomyocardial biopsy in the hands of the electrophysiologist: the 'one-stop shop' for arrhythmic non-ischaemic cardiomyopathy. Letter regarding the article 'Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Fai
    Eur J Heart Fail. 2021 Sep 10. doi: 10.1002/ejhf.2340.
    PubMed    


  480. MEIJERS WC, Bayes-Genis A, Mebazaa A, Bauersachs J, et al
    Circulating Heart Failure Biomarkers beyond Natriuretic Peptides: updated review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2346.
    PubMed     Abstract available


  481. INCIARDI RM, Solomon SD
    Cardiac Mechanics Assessment and the Risk of Heart Failure in the General Population.
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2342.
    PubMed    


  482. HEUSSER K, Wittkoepper J, Bara C, Haverich A, et al
    Sympathetic vasoconstrictor activity before and after left ventricular assist device implantation in patients with end-stage heart failure.
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2344.
    PubMed     Abstract available


  483. BARTKO PE, Kreidel F, von Bardeleben RS, Goliasch G, et al
    Mitral regurgitation tips the scales in acute or worsening heart failure.
    Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2343.
    PubMed    


  484. MOURA B, Aimo A, Al-Mohammad A, Flammer A, et al
    Integration of imaging and circulating biomarkers in heart failure: a Consensus Document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2021 Sep 5. doi: 10.1002/ejhf.2339.
    PubMed     Abstract available


  485. BECHER PM, Schrage B, Benson L, Fudim M, et al
    Phenotyping Heart Failure Patients for Iron Deficiency and Use of Intravenous Iron Therapy: Data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2021 Sep 3. doi: 10.1002/ejhf.2338.
    PubMed     Abstract available



  486. Abstracts of the Heart Failure 2021 and the World Congress on Acute Heart Failure, 29 June - 1 July 2021, Online Congress.
    Eur J Heart Fail. 2021;23 Suppl 2:2-322.
    PubMed    


  487. CRESPO-LEIRO MG, Barge-Caballero E, Gustafsson F
    Efficacy of the COVID-19 vaccine in heart transplant recipients: what we know and what we ignore.
    Eur J Heart Fail. 2021;23:1560-1562.
    PubMed    


  488. ITZHAKI BEN ZADOK O, Shaul AA, Ben-Avraham B, Yaari V, et al
    Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study.
    Eur J Heart Fail. 2021;23:1555-1559.
    PubMed     Abstract available


  489. TOMASONI D, Adamo M, Metra M
    September 2021 at a glance: focus on biomarkers, sex differences and adherence to medical treatment.
    Eur J Heart Fail. 2021;23:1419-1421.
    PubMed    


  490. BLUMER V, Gayowsky A, Xie F, Greene SJ, et al
    Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the PACT-HF randomized controlled trial.
    Eur J Heart Fail. 2021;23:1488-1498.
    PubMed     Abstract available


  491. TOPS LF, Coats AJS, Ben Gal T
    The ever-changing field of mechanical circulatory support: new challenges at the advent of the 'single device era'.
    Eur J Heart Fail. 2021;23:1428-1431.
    PubMed    


  492. AIMO A, Saccaro LF, Borrelli C, Fabiani I, et al
    The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease.
    Eur J Heart Fail. 2021;23:1458-1467.
    PubMed     Abstract available


  493. YUZEFPOLSKAYA M, Colombo PC
    Reply to 'Existing evidence supports clinical trials on interventions preventing ventricular assist device infection in patients colonized with Staphylococcus aureus'.
    Eur J Heart Fail. 2021;23:1566-1567.
    PubMed    


  494. NURJADI D, Ruhparwar A, Zanger P
    Existing evidence supports clinical trials on interventions preventing ventricular assist device infection in patients colonized with Staphylococcus aureus. Letter regarding the article 'Association of preoperative infections, nasal Staphylococcus aur
    Eur J Heart Fail. 2021;23:1566.
    PubMed    


  495. FERREIRA JP, Konstam MA, McMurray JJV, Butler J, et al
    Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial.
    Eur J Heart Fail. 2021;23:1477-1484.
    PubMed     Abstract available


    August 2021
  496. CARBONE S, DaSilva-deAbreu A, Lavie CJ
    The SGLT2 Inhibitor Dapagliflozin Improves Prognosis in Systolic Heart Failure Independent of the Obesity Paradox.
    Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2336.
    PubMed    


  497. DANDEL M, Hetzer R
    Benefits of Transvenous Mitral Annuloplasty in Heart Failure with Lower Degrees of Functional Mitral Regurgitation. Letter regarding the article ' Treating symptoms and reversing remodeling: clinical and echocardiographic 1-year outcomes with percutan
    Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2335.
    PubMed    


  498. PUGLIESE NR, Paneni F, Mazzola M, De Biase N, et al
    Impact of epicardial adipose tissue on cardiovascular hemodynamics, metabolic profile, and prognosis in heart failure.
    Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2337.
    PubMed     Abstract available


  499. RICHARDS AM, Pemberton CJ
    Progress in proteomic probing for pathogenic pathways in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021 Aug 18. doi: 10.1002/ejhf.2332.
    PubMed    


  500. STEWART COATS A
    Figures of the Heart Failure Association: Professor Dr. Wilfried Mullens, Board Member, 2018-2022, Coordinator of Study Group of Cardiorenal Dysfunction and Co-coordinator of Committee on Cardiac Devices.
    Eur J Heart Fail. 2021 Aug 9. doi: 10.1002/ejhf.2325.
    PubMed    


  501. STEWART COATS AJ
    Figures of the Heart Failure Association: Loreena Hill (HFA Board Member and Nurse representative 2016-2020, and HFA Secretary 2020-2022).
    Eur J Heart Fail. 2021 Aug 6. doi: 10.1002/ejhf.2323.
    PubMed    


  502. STEWART COATS AJ
    The HFA further develops it educational engagement working together on an MSc in Heart Failure with St George's Hospital in London.
    Eur J Heart Fail. 2021 Aug 6. doi: 10.1002/ejhf.2324.
    PubMed    


  503. TOMASONI D, Adamo M, Metra M
    August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices.
    Eur J Heart Fail. 2021;23:1247-1249.
    PubMed    


  504. HERRINGTON WG, Savarese G, Haynes R, Marx N, et al
    Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
    Eur J Heart Fail. 2021;23:1260-1275.
    PubMed     Abstract available


  505. SINAGRA G, Dal Ferro M, Gigli M
    The heart of dystrophinopathies.
    Eur J Heart Fail. 2021;23:1287-1289.
    PubMed    


  506. GUSTAFSSON F, Netuka I
    Progressive elimination of adverse events: the key to success for left ventricular assist devices.
    Eur J Heart Fail. 2021;23:1401-1403.
    PubMed    


  507. ROSARIO KF, DeVore AD
    Can we prevent infections in patients with left ventricular assist devices?
    Eur J Heart Fail. 2021;23:1416-1418.
    PubMed    


  508. RESTREPO-CORDOBA MA, Wahbi K, Florian AR, Jimenez-Jaimez J, et al
    Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy.
    Eur J Heart Fail. 2021;23:1276-1286.
    PubMed     Abstract available


  509. RAPEZZI C, Pavasini R, Serenelli M
    The left atrium in cardiac amyloidosis: a valuable but still underused observation window on the overall disease process.
    Eur J Heart Fail. 2021;23:1296-1299.
    PubMed    


  510. YUZEFPOLSKAYA M, Lumish HS, Javaid A, Cagliostro B, et al
    Association of preoperative infections, nasal Staphylococcus aureus colonization and gut microbiota with left ventricular assist device outcomes.
    Eur J Heart Fail. 2021;23:1404-1415.
    PubMed     Abstract available


  511. MEHRA MR, Cleveland JC Jr, Uriel N, Cowger JA, et al
    Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants.
    Eur J Heart Fail. 2021;23:1392-1400.
    PubMed     Abstract available


  512. IUNG B, Urena M
    Transcatheter mitral valve repair for primary and secondary mitral regurgitation: new insights from a nationwide registry.
    Eur J Heart Fail. 2021;23:1377-1379.
    PubMed    


  513. MINAMISAWA M, Inciardi RM, Claggett B, Cuddy SAM, et al
    Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans.
    Eur J Heart Fail. 2021;23:1290-1295.
    PubMed     Abstract available


  514. COLOMBO A, Mangieri A
    Can we set a threshold for the learning curve of MitraClip procedures?
    Eur J Heart Fail. 2021;23:1390-1391.
    PubMed    


  515. CHATTERJEE NA, Levy WC
    Looking forward and backward for sudden death risk: competing risk is everywhere.
    Eur J Heart Fail. 2021;23:1357-1360.
    PubMed    


  516. KELLER K, Hobohm L, Schmidtmann I, Munzel T, et al
    Centre procedural volume and adverse in-hospital outcomes in patients undergoing percutaneous transvenous edge-to-edge mitral valve repair using MitraClip(R) in Germany.
    Eur J Heart Fail. 2021;23:1380-1389.
    PubMed     Abstract available


  517. BEDOGNI F, Popolo Rubbio A, Grasso C, Adamo M, et al
    Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and residual mitral regurgitation after MitraClip implantation.
    Eur J Heart Fail. 2021;23:1364-1376.
    PubMed     Abstract available


  518. GILL H, Chehab O, Allen C, Patterson T, et al
    The advantages, pitfalls and limitations of guideline-directed medical therapy in patients with valvular heart disease.
    Eur J Heart Fail. 2021;23:1325-1333.
    PubMed     Abstract available


    July 2021
  519. SKAARUP KG, Lassen MCH, Johansen ND, Sengelov M, et al
    Layer-Specific Global Longitudinal Strain and the Risk of Heart Failure and Cardiovascular Mortality in the General Population: The Copenhagen City Heart Study.
    Eur J Heart Fail. 2021 Jul 29. doi: 10.1002/ejhf.2315.
    PubMed     Abstract available


  520. PANDEY A, Butler J
    Improving Exercise Tolerance & Quality of Life in Heart Failure with Preserved Ejection Fraction Time to Think Outside the Heart.
    Eur J Heart Fail. 2021 Jul 22. doi: 10.1002/ejhf.2313.
    PubMed    


  521. KHAN MS, Butler J, Greene SJ
    Simultaneous or Rapid Sequence Initiation of Medical Therapies for Heart Failure: Seeking to Avoid the Case of "Too Little, Too Late".
    Eur J Heart Fail. 2021 Jul 19. doi: 10.1002/ejhf.2311.
    PubMed    


  522. SWEDBERG K
    The clinical practise of treating patients with chronic heart failure needs to be improved.
    Eur J Heart Fail. 2021 Jul 17. doi: 10.1002/ejhf.2309.
    PubMed    


  523. ADAMSON C, Jhund PS, Docherty KF, Belohlavek J, et al
    Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.
    Eur J Heart Fail. 2021 Jul 16. doi: 10.1002/ejhf.2308.
    PubMed     Abstract available


  524. MILLER RJ, Howlett JG
    Untying the Gordian Knot of Sex and Heart Failure Therapy.
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2299.
    PubMed    


  525. SAVARESE G, Merlo M, Coats AJ, Metra M, et al
    Best of European Journal of Heart Failure at the ESC/HFA Heart Failure Congress 2021.
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2306.
    PubMed    


  526. ANKER MS, Tschope C
    Reply to 'Heart failure with preserved ejection fraction and COVID-19: which comes first, the chicken or the egg?'
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2305.
    PubMed    


  527. GRAHAM FJ, Pellicori P, Cleland JGF, Clark AL, et al
    REPLY to a letter regarding the article "Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure".
    Eur J Heart Fail. 2021 Jul 14. doi: 10.1002/ejhf.2304.
    PubMed    


  528. GREENE SJ, Butler J, Metra M
    Another Reason to Embrace Quadruple Medical Therapy for Heart Failure: Medications Enabling Tolerance of the Others.
    Eur J Heart Fail. 2021 Jul 14. doi: 10.1002/ejhf.2301.
    PubMed    


  529. NUNEZ J, de la Espriella R, Minana G, Santas E, et al
    Antigen Carbohydrate 125 as a Biomarker in Heart Failure: a Narrative Review.
    Eur J Heart Fail. 2021 Jul 9. doi: 10.1002/ejhf.2295.
    PubMed     Abstract available


  530. KRESOJA KP, Rommel KP, Wachter R, Henger S, et al
    Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2291.
    PubMed     Abstract available


  531. BAYES-GENIS A, Januzzi JL, Richards AM, Arfsten H, et al
    The "Peptide for Life" Initiative: A Call for Action to Provide Equal Access for the Use of Natriuretic Peptides in the Diagnosis of Acute Heart Failure across Europe.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2293.
    PubMed    


  532. BISSON A, Ding WY, Bodin A, Lip GYH, et al
    Clinical outcomes with digoxin vs beta-blocker for heart rate control in permanent atrial fibrillation with heart failure.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2292.
    PubMed    


  533. CARAVITA S, Iacovoni A, Senni M
    The right side of the circulation in not secondary heart failure with preserved ejection fraction: an elephant in the room?
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2294.
    PubMed    


  534. TOMASONI D, Adamo M, Metra M
    July 2021 at a glance: focus on blood volume distribution, haemodynamics and adherence to therapy.
    Eur J Heart Fail. 2021;23:1059-1061.
    PubMed    


  535. MEHRA MR, Crandall DL, Gustafsson F, Jorde UP, et al
    Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial.
    Eur J Heart Fail. 2021;23:1226-1237.
    PubMed     Abstract available


  536. TURNER JM, Cox ZL, Testani JM
    Improving renal function during diuresis: useful information or just noise?
    Eur J Heart Fail. 2021;23:1131-1133.
    PubMed    


  537. AMMIRATI E, Varrenti M, Veronese G, Fanti D, et al
    Prevalence and outcome of patients with acute myocarditis and positive viral search on nasopharyngeal swab.
    Eur J Heart Fail. 2021;23:1242-1245.
    PubMed    


  538. PELLICORI P, Fitchett D, Kosiborod MN, Ofstad AP, et al
    Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.
    Eur J Heart Fail. 2021;23:1085-1093.
    PubMed     Abstract available


  539. KUSCHYK J, Falk P, Demming T, Marx O, et al
    Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system.
    Eur J Heart Fail. 2021;23:1160-1169.
    PubMed     Abstract available


  540. DENIAU B, Picod A, Azibani F, Gayat E, et al
    The CLIP-based mortality score in cardiogenic shock: suitable only for cardiogenic shock?
    Eur J Heart Fail. 2021;23:1240-1242.
    PubMed    


  541. ZYMLINSKI R, Biegus J, Ponikowski P
    Not all fluid overloads are the same: some practical considerations for better decongestion.
    Eur J Heart Fail. 2021;23:1106-1109.
    PubMed    


  542. KARAMICHALAKIS N, Ikonomidis I, Parissis J, Simitsis P, et al
    Association of ventricular-arterial interaction with the response to cardiac resynchronization therapy.
    Eur J Heart Fail. 2021;23:1238-1240.
    PubMed    


  543. FINOCCHIARO G, Sinagra G, Papadakis M, Carr-White G, et al
    The labyrinth of nomenclature in Cardiology. Eternal dilemmas and new challenges on the horizon in the personalized medicine era.
    Eur J Heart Fail. 2021;23:1062-1067.
    PubMed    


    June 2021
  544. PONIKOWSKI P, Alemayehu W, Oto A, Bahit MC, et al
    Vericiguat in Patients with Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA trial.
    Eur J Heart Fail. 2021 Jun 30. doi: 10.1002/ejhf.2285.
    PubMed     Abstract available


  545. MCEWAN P, Ponikowski P, Davis JA, Rosano G, et al
    Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.
    Eur J Heart Fail. 2021 Jun 30. doi: 10.1002/ejhf.2270.
    PubMed     Abstract available


  546. YAFASOVA A, Butt JH, Rorth R
    Troponin - An important prognostic biomarker in patients with heart failure and reduced ejection fraction?
    Eur J Heart Fail. 2021 Jun 29. doi: 10.1002/ejhf.2282.
    PubMed    


  547. GREENE SJ, Fonarow GC
    Clinical Inertia and Medical Therapy for Heart Failure: The Unintended Harms of "First, Do No Harm".
    Eur J Heart Fail. 2021 Jun 29. doi: 10.1002/ejhf.2283.
    PubMed    


  548. ABDIN A, Bohm M
    Renal function and vericiguat in heart failure patients: Light at the end of the tunnel!
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2280.
    PubMed    


  549. KHAN MS, Khan F, Fonarow GC, Sreenivasan J, et al
    Dietary Interventions and Nutritional Supplements for Heart Failure: A Systematic Appraisal and Evidence Map.
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2278.
    PubMed     Abstract available


  550. ANKER SD, Khan MS, Shahid I, Filippatos G, et al
    SGLT-2 Inhibitors in Heart Failure with Preserved Ejection Fraction Reasons for Optimism.
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2279.
    PubMed    


  551. SHAH SJ, Cowie MR, Wachter R, Szecsody P, et al
    Baseline Characteristics of Patients in the PARALLAX Trial: Insights into Quality of Life and Exercise Capacity in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jun 25. doi: 10.1002/ejhf.2277.
    PubMed     Abstract available


  552. PAGNESI M, Adamo M, Sama IE, Anker SD, et al
    Impact of mitral regurgitation in patients with worsening heart failure: Insights from BIOSTAT-CHF.
    Eur J Heart Fail. 2021 Jun 23. doi: 10.1002/ejhf.2276.
    PubMed     Abstract available


  553. BARATTO C, Caravita S, Parati G
    HFpEF and COVID-19: which comes first, the chicken or the egg? Letter regarding the article "Heart Failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings".
    Eur J Heart Fail. 2021 Jun 17. doi: 10.1002/ejhf.2273.
    PubMed    


  554. SAVARESE G, Bodegard J, Norhammar A, Sartipy P, et al
    Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
    Eur J Heart Fail. 2021 Jun 15. doi: 10.1002/ejhf.2271.
    PubMed     Abstract available


  555. RICHARDS AM, Pemberton CJ
    Urinary Peptides in Heart Failure - the need for care with pees and cues.
    Eur J Heart Fail. 2021 Jun 12. doi: 10.1002/ejhf.2269.
    PubMed    


  556. PATEL RB, Shah SJ
    The Splanchnic Reservoir: An Oasis for Blood Volume in Heart Failure with Preserved Ejection Fraction?
    Eur J Heart Fail. 2021 Jun 12. doi: 10.1002/ejhf.2268.
    PubMed    


  557. STOLFO D, Savarese G
    Association Between Heart Failure and Cancer: Is Gender the Answer?
    Eur J Heart Fail. 2021 Jun 11. doi: 10.1002/ejhf.2261.
    PubMed    


  558. BHATT AS, Vaduganathan M, Claggett BL, Liu J, et al
    Effect of Sacubitril/Valsartan versus Enalapril on Changes in Heart Failure Therapies Over Time: The PARADIGM-HF Trial.
    Eur J Heart Fail. 2021 Jun 7. doi: 10.1002/ejhf.2259.
    PubMed     Abstract available


  559. TOMASONI D, Adamo M, Metra M
    June 2021 at a glance: focus on epidemiology, biomarkers and medical treatment.
    Eur J Heart Fail. 2021;23:847-849.
    PubMed    


  560. SEGAR MW, Pandey A
    Omics, machine learning, and personalized medicine in heart failure with preserved ejection fraction: promising future or false hope?
    Eur J Heart Fail. 2021;23:992-994.
    PubMed    


  561. FERREIRA JP
    Circulating levels of procollagen type I carboxy-terminal propeptide reflect myocardial fibrosis.
    Eur J Heart Fail. 2021;23:945-946.
    PubMed    


  562. RAAFS AG, Verdonschot JAJ, Henkens MTHM, Adriaans BP, et al
    The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy - A multilevel assessment o
    Eur J Heart Fail. 2021;23:933-944.
    PubMed     Abstract available


  563. GARCIA-PAVIA P, Bengel F, Brito D, Damy T, et al
    Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy.
    Eur J Heart Fail. 2021;23:895-905.
    PubMed     Abstract available


  564. HAVERKAMP W, Butler J, Anker SD
    Can we trust a smartwatch ECG? Potential and limitations.
    Eur J Heart Fail. 2021;23:850-853.
    PubMed    


  565. SATTAR N, Januzzi JL
    Can biomarkers help find the 'sweet spot' for treating patients with diabetes?
    Eur J Heart Fail. 2021;23:1037-1039.
    PubMed    


  566. PARCHA V, Arora P
    Sodium-glucose co-transporter 2 inhibitors: strength of evidence for a cardio-renal-metabolic therapy.
    Eur J Heart Fail. 2021;23:1009-1011.
    PubMed    


  567. GREENBERG B, Adler E, Campagnari C, Yagil A, et al
    A machine learning risk score predicts mortality across the spectrum of left ventricular ejection fraction.
    Eur J Heart Fail. 2021;23:995-999.
    PubMed     Abstract available


  568. DAMY T, Sultan MB, Witteles R
    Reply to the letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.
    Eur J Heart Fail. 2021;23:1057-1058.
    PubMed    


    May 2021
  569. PACKER M, Januzzi JL Jr, Ferreira JP, Anker SD, et al
    Concentration-Dependent Clinical and Prognostic Importance of High-Sensitivity Cardiac Troponin T in Heart Failure and a Reduced Ejection Fraction and the Influence of Empagliflozin: the EMPEROR-Reduced Trial.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2256.
    PubMed     Abstract available


  570. BUTLER J, Yang M, Sawhney B, Chakladar S, et al
    Treatment Patterns and Clinical Outcomes Among Patients <65 Years with a Worsening Heart Failure Event.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2252.
    PubMed     Abstract available


  571. SORIMACHI H, Burkhoff D, Verbrugge FH, Omote K, et al
    Obesity, Venous Capacitance, and Venous Compliance in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2254.
    PubMed     Abstract available


  572. SOLOMON SD, de Boer RA, DeMets D, Hernandez AF, et al
    Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
    Eur J Heart Fail. 2021 May 29. doi: 10.1002/ejhf.2249.
    PubMed     Abstract available


  573. TKACZYSZYN M, Comin-Colet J, Voors AA, van Veldhuisen DJ, et al
    Iron deficiency contributes to the resistance to endogenous erythropoietin in anaemic heart failure patients.
    Eur J Heart Fail. 2021 May 29. doi: 10.1002/ejhf.2253.
    PubMed     Abstract available


  574. GRAHAM FJ, Masini G, Pellicori P, Cleland JGF, et al
    Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure.
    Eur J Heart Fail. 2021 May 28. doi: 10.1002/ejhf.2251.
    PubMed     Abstract available


  575. FADINI GP, Avogaro A
    A simple way to spotlight hidden heart failure in type 2 diabetes?
    Eur J Heart Fail. 2021 May 28. doi: 10.1002/ejhf.2258.
    PubMed    


  576. VAN SPALL HG, Averbuch T, Damman K, Voors AA, et al
    Risk and Risk Reduction In Trials of Heart Failure with Reduced Ejection Fraction: Absolute or Relative?
    Eur J Heart Fail. 2021 May 26. doi: 10.1002/ejhf.2248.
    PubMed    


  577. SEFEROVIC PM, Tsutsui H, McNamara DM, Ristic AD, et al
    Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy.
    Eur J Heart Fail. 2021 May 19. doi: 10.1002/ejhf.2190.
    PubMed     Abstract available


  578. VOORS AA, Mulder H, Reyes E, Cowie MR, et al
    Renal Function and the Effects of Vericiguat in Patients with Worsening Heart Failure with Reduced Ejection Fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF) Trial.
    Eur J Heart Fail. 2021 May 17. doi: 10.1002/ejhf.2221.
    PubMed     Abstract available


  579. BRAUNWALD E
    The War on Heart Failure.
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2217.
    PubMed    


  580. KAPELIOS CJ, Canepa M, Savarese G, Lund LH, et al
    Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratian principle "do no harm"?
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2218.
    PubMed    


  581. BISTOLA V, Simitsis P, Parissis J, Ouwerkerk W, et al
    Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum.
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2219.
    PubMed     Abstract available


  582. KAPELIOS CJ, Canepa M, Savarese G, Lund LH, et al
    Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratian principle "do no harm"?
    Eur J Heart Fail. 2021 May 8. doi: 10.1002/ejhf.2214.
    PubMed    


  583. TOCCHETTI CG, Mercurio V, Maack C
    The multifaceted mechanisms of nitroxyl in heart failure: Inodilator or "only" vasodilator?
    Eur J Heart Fail. 2021 May 2. doi: 10.1002/ejhf.2204.
    PubMed    


  584. HILL L, Lambrinou E, Antoniou S
    Optimizing evidence-based heart failure medication: Every contact counts.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2213.
    PubMed    


  585. ROSANO GMC, Moura B, Metra M, Bauersachs J, et al
    Patients profiling in Heart Failure for tailoring medical therapy A consensus document of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2206.
    PubMed    


  586. LEEDY DJ, Reding KW, Vasbinder AL, Anderson GL, et al
    The association between heart failure and incident cancer in women: An analysis of the Women's Health Initiative.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2207.
    PubMed     Abstract available


  587. MALEK F, Gajewski P, Zymlinski R, Janczak D, et al
    Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: First-in-human clinical trial.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2209.
    PubMed     Abstract available


  588. MULDER BA, van Veldhuisen DJ, Rienstra M
    Sudden cardiac death in heart failure: more than meets the eye.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2212.
    PubMed    


  589. HADZIBEGOVIC S, Lena A, Churchill TW, Ho JE, et al
    Heart Failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2210.
    PubMed     Abstract available


  590. TOMASONI D, Adamo M, Metra M
    May 2021 at a glance: focus on acute heart failure and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021;23:691-692.
    PubMed    


  591. MULLENS W, Martens P, Witte K, Cowie MR, et al
    Reply to 'Why mechanical dyssynchrony remains relevant to cardiac resynchronization therapy'.
    Eur J Heart Fail. 2021;23:844-845.
    PubMed    


  592. TOMASONI D, Coats AJS
    The Altmetric Attention Score: how science tries to meet social media.
    Eur J Heart Fail. 2021;23:693-697.
    PubMed    


  593. SUGUMAR H, Nanayakkara S, Vizi D, Wright L, et al
    A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF.
    Eur J Heart Fail. 2021;23:785-796.
    PubMed     Abstract available


  594. KHEDRAKI R, Tang WHW
    Identifying sodium non-excretors: heart failure's emerging golden ticket for risk stratification.
    Eur J Heart Fail. 2021;23:740-742.
    PubMed    


  595. VEENIS JF, Brugts JJ, Yalcin YC, Caliskan K, et al
    Reply to 'Aortic valve surgery and left ventricular assist device: lights and shadows'.
    Eur J Heart Fail. 2021;23:842-843.
    PubMed    


  596. LOARDI C, Zanobini M
    Aortic valve surgery and left ventricular assist device: lights and shadows. Letter regarding the article 'Survival following a concomitant aortic valve procedure during left ventricular assist device surgery: an ISHLT Mechanically Assisted Circulator
    Eur J Heart Fail. 2021;23:841-842.
    PubMed    


  597. BHATT AS, Yanamandala M, Konstam MA
    For vaptans, as for life, balance is better.
    Eur J Heart Fail. 2021;23:751-753.
    PubMed    


  598. SANDERS-VAN WIJK S, Barandiaran Aizpurua A, Brunner-La Rocca HP, Henkens MTHM, et al
    The HFA-PEFF and H2 FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021;23:838-840.
    PubMed    


    April 2021
  599. FRASER AG, Tschope C, de Boer RA
    Diagnostic recommendations and phenotyping for heart failure with preserved ejection fraction - knowing more and understanding less?
    Eur J Heart Fail. 2021 Apr 30. doi: 10.1002/ejhf.2205.
    PubMed    


  600. BEUSEKAMP JC, Tromp J, Boorsma EM, Heerspink HJL, et al
    Effects of SGLT2 inhibition with Empagliflozin on Potassium Handling in Patients with Acute Heart Failure.
    Eur J Heart Fail. 2021 Apr 26. doi: 10.1002/ejhf.2197.
    PubMed    


  601. FUDIM M, Ponikowski P, Burkhoff D, Dunlap M, et al
    Splanchnic Nerve Modulation in Heart Failure: Mechanistic Overview, Initial Clinical Experience, and Safety Considerations.
    Eur J Heart Fail. 2021 Apr 22. doi: 10.1002/ejhf.2196.
    PubMed     Abstract available


  602. HE T, Mischak M, Clark AL, Campbell RT, et al
    Urinary peptides in heart failure: a link to molecular pathophysiology.
    Eur J Heart Fail. 2021 Apr 21. doi: 10.1002/ejhf.2195.
    PubMed     Abstract available


  603. FINE NM, Howlett JG
    Cautious optimism for machine learning techniques for prediction of heart failure outcomes.
    Eur J Heart Fail. 2021 Apr 20. doi: 10.1002/ejhf.2192.
    PubMed    


  604. NASSIF M, Butler J
    Moving in the Right Direction but Not There Yet. The Utility, Measurement, and Analysis of Health Status in Heart Failure Trials.
    Eur J Heart Fail. 2021 Apr 20. doi: 10.1002/ejhf.2193.
    PubMed    


  605. JERING KS, Claggett B, Pfeffer MA, Granger C, et al
    Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics.
    Eur J Heart Fail. 2021 Apr 12. doi: 10.1002/ejhf.2191.
    PubMed     Abstract available


  606. BAYES-GENIS A, Lupon J
    Heart failure is ejection fraction in motion.
    Eur J Heart Fail. 2021 Apr 9. doi: 10.1002/ejhf.2185.
    PubMed    


  607. ABRAHAM WT
    Interatrial Shunting for the Treatment of Heart Failure: An On-Demand, Self-Regulating Left Atrial Pressure Lowering System.
    Eur J Heart Fail. 2021 Apr 8. doi: 10.1002/ejhf.2184.
    PubMed    


  608. SORENSEN TB, Minamisawa M, Liu J, Claggett B, et al
    The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (COSMIC -HF).
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2181.
    PubMed    


  609. FERREIRA JP
    Cognitive function assessment for personalized heart failure disease management programmes.
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2183.
    PubMed    


  610. GIRERD N, Felker GM
    The lower is not always the better: a better understanding of loop diuretics in heart failure.
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2182.
    PubMed    


  611. BOLLI R, Mitrani RD, Hare JM, Pepine CJ, et al
    A Phase II Study of Autologous Mesenchymal Stromal Cells and c-kit Positive Cardiac Cells, Alone or in Combination, in Patients with Ischemic Heart Failure: The CCTRN CONCERT-HF Trial.
    Eur J Heart Fail. 2021 Apr 3. doi: 10.1002/ejhf.2178.
    PubMed     Abstract available


  612. PAGNESI M, Adamo M, Metra M
    April 2021 at a glance: focus on systolic function, quality of life and treatment in heart failure.
    Eur J Heart Fail. 2021;23:505-506.
    PubMed    


  613. BAYES-GENIS A
    The CONCERT-HF trial: a sweet and sour symphony.
    Eur J Heart Fail. 2021;23:675-676.
    PubMed    


  614. GARCIA-PAVIA P, Rapezzi C, Adler Y, Arad M, et al
    Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
    Eur J Heart Fail. 2021;23:512-526.
    PubMed     Abstract available


  615. BOUDOULAS KD, Boudoulas H
    Time and left ventricular function: the forgotten dynamic factor.
    Eur J Heart Fail. 2021;23:552-554.
    PubMed    


  616. STRANGE G, Playford D, Scalia GM, Celermajer DS, et al
    Change in ejection fraction and long-term mortality in adults referred for echocardiography.
    Eur J Heart Fail. 2021;23:555-563.
    PubMed     Abstract available


  617. COATS AJS, Rosano G
    Treatments delayed lead to lives lost.
    Eur J Heart Fail. 2021;23:511.
    PubMed    


  618. DOCHERTY KF, Curtain JP, Anand IS, Bengtsson O, et al
    Effect of dapagliflozin on anaemia in DAPA-HF.
    Eur J Heart Fail. 2021;23:617-628.
    PubMed     Abstract available


  619. DOBNER S
    Letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.
    Eur J Heart Fail. 2021;23:681-682.
    PubMed    


  620. HAGNAS MJ, Grasso C, Di Salvo ME, Sardone A, et al
    Effect of post-procedural evidence-based therapy on 2-year prognosis after transcatheter mitral valve repair.
    Eur J Heart Fail. 2021;23:677-679.
    PubMed    


    March 2021
  621. WETTERSTEN N, Horiuchi Y, van Veldhuisen DJ, Ix JH, et al
    Decongestion Discriminates Risk for One Year Mortality in Patients with Improving Renal Function in Acute Heart Failure.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2179.
    PubMed     Abstract available


  622. HUYNH QL, Whitmore K, Negishi K, DePasquale CG, et al
    Cognitive Impairment as a Determinant of Response to Management Plans After Heart Failure Admission.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2177.
    PubMed     Abstract available


  623. BARAKAT MF, Amin-Youseff G, Okonko DO
    Oral Sucrosomial Iron in Heart Failure with a Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2176.
    PubMed    


  624. UIJL A, Savarese G, Vaartjes I, Dahlstrom U, et al
    Identification of Distinct Phenotypic Clusters in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2169.
    PubMed     Abstract available


  625. KALOGEROPOULOS AP, Hotelling J, Skopicki HA
    Blood Counts: Targeting Anemia in Patients with Heart Failure.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2173.
    PubMed    


  626. KHAN MS, Fonarow GC, Greene SJ
    SGLT-2 Inhibitors for Heart Failure: Clinical Trial Efficacy and Clinical Practice Effectiveness.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2170.
    PubMed    


  627. WAN SH, Pandey A
    Targeting the nitrate-nitrite-nitric oxide pathway in heart failure with preserved ejection fraction: too soon to say no to nitric oxide?
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2171.
    PubMed    


  628. KHAN MS, Usman MS, Butler J
    Etiology Of Heart Failure Is In The Eye Of The Beholder: Does It Even Matter?
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2166.
    PubMed    


  629. PACKER M
    What Causes Exertional Dyspnea in Patients With Atrial Fibrillation? Implications for Catheter Ablation in Patients With Heart Failure.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2164.
    PubMed    


  630. BHATT AS, Varshney AS, Nekoui M, Moscone A, et al
    Virtual Optimization of Guideline-Directed Medical Therapy in Hospitalized Patients with Heart Failure with Reduced Ejection Fraction: the IMPLEMENT-HF Pilot Study.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2163.
    PubMed     Abstract available


  631. METRA M, Coats AJS
    Why we love heart failure. An introduction to the universal definition of heart failure.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2168.
    PubMed    


  632. GUPTA P, Voors AA, Patel P, Lane D, et al
    Non-adherence to heart failure medications predicts clinical outcomes: Assessment in a single spot urine sample by liquid chromatography - tandem mass spectrometry (results of a prospective multicentre study).
    Eur J Heart Fail. 2021 Mar 23. doi: 10.1002/ejhf.2160.
    PubMed    


  633. CHIONCEL O, Stewart Coats AJ
    National Heart Failure Societies Summit 2020.
    Eur J Heart Fail. 2021 Mar 21. doi: 10.1002/ejhf.2157.
    PubMed    


  634. BOORSMA EM, Ter Maaten JM, Damman K, van Veldhuisen DJ, et al
    Dipeptidyl peptidase-3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure.
    Eur J Heart Fail. 2021 Mar 20. doi: 10.1002/ejhf.2158.
    PubMed     Abstract available


  635. RAVERA A, Santema BT, Sama IE, Meyer S, et al
    Quality of life in men and women with heart failure: association with outcome, and comparison of the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire.
    Eur J Heart Fail. 2021 Mar 16. doi: 10.1002/ejhf.2154.
    PubMed     Abstract available


  636. TROMP J, Bryant JA, Jin X, van Woerden G, et al
    Epicardial fat in heart failure with reduced versus preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 16. doi: 10.1002/ejhf.2156.
    PubMed    


  637. ZIAEIAN B, Fonarow GC
    Making heart failure count.
    Eur J Heart Fail. 2021 Mar 13. doi: 10.1002/ejhf.2148.
    PubMed    


  638. PACKER M, McMurray JJV
    Rapid Evidence-Based Sequencing of Foundational Drugs for Heart Failure and a Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 11. doi: 10.1002/ejhf.2149.
    PubMed     Abstract available


  639. PUVREZ A, Duchenne J, Gorcsan J 3rd, Marwick TH, et al
    Why mechanical dyssynchrony remains relevant to cardiac resynchronization therapy. Letter regarding the article 'Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position s
    Eur J Heart Fail. 2021 Mar 11. doi: 10.1002/ejhf.2150.
    PubMed    


  640. WOLSK E, Kaye DM, Komtebedde J, Shah SJ, et al
    Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 8. doi: 10.1002/ejhf.2146.
    PubMed     Abstract available


  641. WOOLLEY RJ, Ceelen D, Ouwerkerk W, Tromp J, et al
    Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 2. doi: 10.1002/ejhf.2144.
    PubMed     Abstract available


  642. CARAVITA S, Senni M, Parati G
    Reply to: 'The hyperdynamic circulatory profile of patients with COVID-19-related acute vascular distress syndrome'.
    Eur J Heart Fail. 2021;23:493-494.
    PubMed    


  643. TOMASONI D, Petrie MC, Adamo M, Metra M, et al
    Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy.
    Eur J Heart Fail. 2021;23:486-488.
    PubMed    


  644. MAHJOUB Y, Rodenstein DO, Jounieaux V
    The hyperdynamic circulatory profile of patients with COVID-19-related acute vascular distress syndrome. Letter regarding the article 'Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical vent
    Eur J Heart Fail. 2021;23:493.
    PubMed    


  645. PAGNESI M, Adamo M, Metra M
    March 2021 at a glance: focus on epidemiology, prevention and COVID-19.
    Eur J Heart Fail. 2021;23:347-349.
    PubMed    


  646. CARO-CODON J, Rey JR, Buno A, Iniesta AM, et al
    Characterization of NT-proBNP in a large cohort of COVID-19 patients.
    Eur J Heart Fail. 2021;23:456-464.
    PubMed     Abstract available


  647. GARG A, Seeliger B, Derda AA, Xiao K, et al
    Circulating cardiovascular microRNAs in critically ill COVID-19 patients.
    Eur J Heart Fail. 2021;23:468-475.
    PubMed     Abstract available


  648. SAVARESE G, Benson L, Sundstrom J, Lund LH, et al
    Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis.
    Eur J Heart Fail. 2021;23:476-485.
    PubMed     Abstract available


  649. BRAUNWALD E, Antman EM
    The path to universality.
    Eur J Heart Fail. 2021;23:381-383.
    PubMed    


  650. OLSEN FJ, Solomon SD, Biering-Sorensen T
    Piecing together the puzzle of sex-specific differences in left ventricular ejection fraction.
    Eur J Heart Fail. 2021;23:417-419.
    PubMed    


  651. CHESSA M, Tutarel O
    Adults with congenital heart disease - we need more Europe for a better care.
    Eur J Heart Fail. 2021;23:454-455.
    PubMed    


  652. STEWART S, Playford D, Scalia GM, Currie P, et al
    Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men.
    Eur J Heart Fail. 2021;23:406-416.
    PubMed     Abstract available


  653. BRIDA M, Simkova I, Jovovic L, Prokselj K, et al
    European Society of Cardiology Working Group on Adult Congenital Heart Disease and Study Group for Adult Congenital Heart Care in Central and South Eastern European Countries consensus paper: current status, provision gaps and investment required.
    Eur J Heart Fail. 2021;23:445-453.
    PubMed     Abstract available


  654. SPERRY BW, Tang Y, Jones PG, Spertus JA, et al
    Cumulative events in the TOPCAT trial.
    Eur J Heart Fail. 2021;23:491-492.
    PubMed    


  655. ITO M, Matsue Y, Minamino T
    Worsening renal function during intensive blood pressure control: another example of not prognostically relevant creatinine rise?
    Eur J Heart Fail. 2021;23:393-395.
    PubMed    


    February 2021
  656. DAUW J, Martens P, Tersalvi G, Schouteden J, et al
    Diuretic Response and Effects of Diuretic Omission in Ambulatory Heart Failure Patients on Chronic Low Dose Loop Diuretic Therapy.
    Eur J Heart Fail. 2021 Feb 28. doi: 10.1002/ejhf.2145.
    PubMed     Abstract available


  657. PASCUAL-FIGAL DA
    Biochemical or clinical heart failure, not so simple.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2128.
    PubMed    


  658. SEFEROVIC PM, Vardas P, Jankowska EA, Maggioni AP, et al
    The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2143.
    PubMed     Abstract available


  659. VERBRUGGE FH, Reddy YNV, Sorimachi H, Omote K, et al
    Diagnostic Scores Predict Morbidity and Mortality in Patients Hospitalised for Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2142.
    PubMed     Abstract available


  660. TURGEON RD, Barry AR, Hawkins NM, Ellis UM, et al
    Pharmacotherapy for Heart Failure with Reduced Ejection Fraction and Health-Related Quality of Life: Systematic Review and Meta-Analysis.
    Eur J Heart Fail. 2021 Feb 25. doi: 10.1002/ejhf.2141.
    PubMed     Abstract available


  661. LANG NN, Ahmad FA, Cleland JG, O'Connor CM, et al
    Hemodynamic Effects of the Nitroxyl Donor Cimlanod (BMS-986231) in Chronic Heart Failure: A Randomized Trial.
    Eur J Heart Fail. 2021 Feb 23. doi: 10.1002/ejhf.2138.
    PubMed     Abstract available


  662. TROMP J, Ponikowski P, Salsali A, Angermann CE, et al
    SGLT2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2137.
    PubMed     Abstract available


  663. BHATIA K, Jain V, Gupta K, Bansal A, et al
    Prevention of Heart Failure Events with SGLT-2 Inhibitors Across a Spectrum of Cardio-Renal-Metabolic Risk.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2135.
    PubMed     Abstract available


  664. SLIWA K, van der Meer P, Petrie MC, Frogoudaki A, et al
    Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripar
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2133.
    PubMed     Abstract available


  665. FERREIRA JP, Claggett BL, Liu J, Desai AS, et al
    Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2134.
    PubMed     Abstract available


  666. BOZKURT B, Coats A, Tsutsui H
    A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure Consensus Conference.
    Eur J Heart Fail. 2021 Feb 19. doi: 10.1002/ejhf.2115.
    PubMed    


  667. CHIONCEL O, Ambrosy AP, Maggioni AP
    Temporal Trends in the Outcomes of Acute Heart Failure: Between Consolatory Evidences and Real Progress.
    Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2130.
    PubMed    


  668. BECHER PM, Schrage B, Ferrannini G, Benson L, et al
    Use of Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure and Type 2 Diabetes Mellitus: Data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2131.
    PubMed     Abstract available


  669. BUTT JH, Nicolau JC, Verma S, Docherty KF, et al
    Efficacy and Safety of Dapagliflozin According to Aetiology in Heart Failure with Reduced Ejection Fraction: Insights from the DAPA-HF trial.
    Eur J Heart Fail. 2021 Feb 16. doi: 10.1002/ejhf.2124.
    PubMed     Abstract available


  670. RICHARDS AM
    Cardiac Myosin-Binding Protein C as a candidate biomarker in Heart Failure: rational but not revolutionary.
    Eur J Heart Fail. 2021 Feb 15. doi: 10.1002/ejhf.2126.
    PubMed    


  671. ALHAKAK AS, Teerlink JR, Lindenfeld J, Bohm M, et al
    The Significance of Left Ventricular Ejection Time in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Feb 15. doi: 10.1002/ejhf.2125.
    PubMed     Abstract available


  672. MILLER WL, Sorimachi H, Grill DE, Fischer K, et al
    Contributions of Cardiac Dysfunction and Volume Status to Central Hemodynamics in Chronic Heart Failure.
    Eur J Heart Fail. 2021 Feb 9. doi: 10.1002/ejhf.2121.
    PubMed     Abstract available


  673. ROHDE LE, Vaduganathan M, Claggett BL, Polanczyk CA, et al
    Dynamic Changes in Cardiovascular and Systemic Variables Prior to Sudden Cardiac Death in Heart Failure with Reduced Ejection Fraction: a PARADIGM-HF Analysis.
    Eur J Heart Fail. 2021 Feb 9. doi: 10.1002/ejhf.2120.
    PubMed     Abstract available


  674. VOLTERRANI M, Perrone V, Degli Esposti L
    Reply letter regarding the article "Effects of hyperkalemia and non-adherence to renin angiotensin aldosterone system inhibitors (RAASi) in patients affected by heart failure in Italy: a propensity-matched study".
    Eur J Heart Fail. 2021 Feb 8. doi: 10.1002/ejhf.2123.
    PubMed    


  675. PAITAZOGLOU C, Bergmann MW, Ozdemir R, Pfister R, et al
    One-year results of the first-in-man study investigating the Atrial-Flow-Regulator for left-atrial shunting in symptomatic heart failure patients: the PRELIEVE study.
    Eur J Heart Fail. 2021 Feb 8. doi: 10.1002/ejhf.2119.
    PubMed     Abstract available


  676. COTTER G, Davison BA, Edwards C, Takagi K, et al
    Acute Heart Failure Treatment - A Light at The End of the Tunnel?
    Eur J Heart Fail. 2021 Feb 6. doi: 10.1002/ejhf.2116.
    PubMed    


  677. CLERICO A, Aimo A, Passino C
    The pathophysiological and clinical relevance of combined measurement of natriuretic peptides and cardiac troponins for risk prediction of incident heart failure in community-dwelling individuals.
    Eur J Heart Fail. 2021 Feb 2. doi: 10.1002/ejhf.2112.
    PubMed    



  678. Corrigendum to 'Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology' [Eur J Heart Fail 2020;22:1315-1341].
    Eur J Heart Fail. 2021;23:345.
    PubMed    



  679. Corrigendum to 'Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncolog
    Eur J Heart Fail. 2021;23:345.
    PubMed    


  680. SMITH N, Tampakakis E
    COVID-19 acute respiratory distress syndrome: intriguing haemodynamics of an intriguing syndrome.
    Eur J Heart Fail. 2021;23:208-210.
    PubMed    


  681. PAGNESI M, Adamo M, Metra M
    February 2021 at a glance: focus on amyloidosis, myocarditis and cardiomyopathy.
    Eur J Heart Fail. 2021;23:201-202.
    PubMed    


  682. STOGIOS N, Fezza G, Wong JV, Ross HJ, et al
    Current challenges for using the Kansas City Cardiomyopathy Questionnaire to obtain a standardized patient-reported health status outcome.
    Eur J Heart Fail. 2021;23:205-207.
    PubMed    


  683. ARNOLD SV, Butler J, Spertus JA
    Standardizing the standard: reporting health status in clinical trials.
    Eur J Heart Fail. 2021;23:203-204.
    PubMed    


  684. CASTIGLIONE V, Franzini M, Aimo A, Carecci A, et al
    Use of biomarkers to diagnose and manage cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:217-230.
    PubMed     Abstract available


  685. PERLINI S, Mussinelli R, Salinaro F
    New effective treatment options reinforce disease awareness: the case of transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:290-292.
    PubMed    


  686. LYLE MA, Cooper LT
    Failure of intravenous immunoglobulin to improve cardiac function in parvovirus B19-associated chronic dilated cardiomyopathy.
    Eur J Heart Fail. 2021;23:310-311.
    PubMed    


  687. RAPEZZI C, Aimo A, Emdin M
    Tafamidis is entering the clinical arena for the treatment of transthyretin-related cardiomyopathy: certainties and unmet needs.
    Eur J Heart Fail. 2021;23:286-289.
    PubMed    


  688. ASLEH R, Amir O, Kushwaha SS
    Dynamics of myocardial fibrosis after left ventricular assist device implantation: should speeding up the scar have us scared stiff?
    Eur J Heart Fail. 2021;23:335-338.
    PubMed    


  689. HAZEBROEK MR, Henkens MTHM, Raafs AG, Verdonschot JAJ, et al
    Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial.
    Eur J Heart Fail. 2021;23:302-309.
    PubMed     Abstract available


  690. BONDERMAN D
    How to ATTR-ACT the perfect match?
    Eur J Heart Fail. 2021;23:275-276.
    PubMed    


  691. RAPEZZI C, Giannini F, Campo G
    Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?
    Eur J Heart Fail. 2021;23:259-263.
    PubMed    


  692. BEZARD M, Kharoubi M, Galat A, Poullot E, et al
    Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
    Eur J Heart Fail. 2021;23:264-274.
    PubMed     Abstract available


  693. DAMY T, Garcia-Pavia P, Hanna M, Judge DP, et al
    Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
    Eur J Heart Fail. 2021;23:277-285.
    PubMed     Abstract available


  694. NICOL M, Deney A, Lairez O, Vergaro G, et al
    Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:231-239.
    PubMed     Abstract available


  695. ROSENBLUM H, Masri A, Narotsky DL, Goldsmith J, et al
    Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:250-258.
    PubMed     Abstract available


  696. SINAGRA G, Porcari A, Gentile P, Artico J, et al
    Viral presence-guided immunomodulation in lymphocytic myocarditis: an update.
    Eur J Heart Fail. 2021;23:211-216.
    PubMed     Abstract available


    January 2021
  697. CANEPA M, Ameri P, Lainscak M
    COPD and comorbidities in heart failure: the next frontier of SGLT2 inhibitors?
    Eur J Heart Fail. 2021 Jan 27. doi: 10.1002/ejhf.2109.
    PubMed    


  698. PETRIE MC, Lee MMY, Docherty KF
    Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction?
    Eur J Heart Fail. 2021 Jan 27. doi: 10.1002/ejhf.2108.
    PubMed    


  699. DOCHERTY KF, Vaduganathan M
    OUTSTEP-HF: re-evaluating the role of physical activity measures in drug and device development in heart failure.
    Eur J Heart Fail. 2021 Jan 22. doi: 10.1002/ejhf.2106.
    PubMed    


  700. SUTHAHAR N, Meems LMG, Groothof D, Bakker SJL, et al
    Relationship between Body-Mass Index, Cardiovascular Biomarkers and Incident Heart Failure.
    Eur J Heart Fail. 2021 Jan 14. doi: 10.1002/ejhf.2102.
    PubMed     Abstract available


  701. KIMMOUN A, Takagi K, Gall E, Ishihara S, et al
    Temporal trends in mortality and readmission after acute heart failure: A systematic review and meta-regression in the past four decades.
    Eur J Heart Fail. 2021 Jan 14. doi: 10.1002/ejhf.2103.
    PubMed     Abstract available


  702. KOZHUHAROV N, Wussler D, Kaier T, Strebel I, et al
    Cardiac Myosin-Binding Protein C in the Diagnosis and Risk Stratification of Acute Heart Failure.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2094.
    PubMed     Abstract available


  703. REDDY YNV, Stewart GM, Obokata M, Koepp KE, et al
    Peripheral and Pulmonary Effects of Inorganic-Nitrite during Exercise in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2093.
    PubMed     Abstract available


  704. KARAVIDAS A, Troganis E, Lazaros G, Balta D, et al
    Oral Sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: A non-randomized, open-label, proof-of-concept study.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2092.
    PubMed     Abstract available


  705. TOMASONI D, Adamo M, Metra M
    January 2021 at a glance: focus on sex differences, acute heart failure and exercise capacity.
    Eur J Heart Fail. 2021;23:1-2.
    PubMed    


  706. MULLENS W, Martens P
    Empagliflozin and renal sodium handling: an intriguing smart osmotic diuretic.
    Eur J Heart Fail. 2021;23:79-82.
    PubMed    


  707. FARMAKIS D, Filippatos G
    Arrhythmias in cancer: rhythm is gonna get you!
    Eur J Heart Fail. 2021;23:154-156.
    PubMed    


  708. ANKER MS, von Haehling S, Coats AJS, Riess H, et al
    Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study.
    Eur J Heart Fail. 2021;23:145-153.
    PubMed     Abstract available


  709. CHIONCEL O, Collins SP, Seferovic P
    Does end-organ dysfunction precede or follow cardiogenic shock in acute decompensated heart failure? The two-faced Janus. Reply.
    Eur J Heart Fail. 2021;23:197-198.
    PubMed    


    December 2020
  710. PABEL S, Hamdani N, Sossalla S
    A mechanistic rationale for the investigation of SGLT2 inhibitors in HFpEF - Letter regarding the article 'Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial'.
    Eur J Heart Fail. 2020 Dec 29. doi: 10.1002/ejhf.2091.
    PubMed    


  711. DEWAN P, Docherty KF, Bengtsson O, de Boer RA, et al
    Effects of dapagliflozin in heart failure with reduced ejection fraction, and COPD: An analysis of DAPA-HF.
    Eur J Heart Fail. 2020 Dec 23. doi: 10.1002/ejhf.2083.
    PubMed     Abstract available


  712. ASLAM MI, Jani V, Lin B, Dunkerly-Eyring B, et al
    Pulmonary Artery Pulsatility Index Predicts Right Ventricular Myofilament Dysfunction in Advanced Human Heart Failure.
    Eur J Heart Fail. 2020 Dec 21. doi: 10.1002/ejhf.2084.
    PubMed    


  713. MORIYAMA H, Kohno T, Kohsaka S
    Letter regarding the article "Effects of hyperkalemia and non-adherence to renin angiotensin aldosterone system inhibitors (RAASi) in patients affected by heart failure in Italy: a propensity-matched study".
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2081.
    PubMed    


  714. DAVISON BA, Senger S, Sama IE, Koch GG, et al
    Is Acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF.
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2077.
    PubMed     Abstract available


  715. SCHNEIDER B, Ong P
    Improving female enrolment in randomized clinical trials of heart failure with reduced ejection fraction to ensure evidence-based health care recommendations.
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2078.
    PubMed    


  716. PIEPOLI MF, Hussain RI, Comin-Colet J, Dosantos R, et al
    OUTSTEP-HF: Randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 Dec 13. doi: 10.1002/ejhf.2076.
    PubMed     Abstract available


  717. DOCHERTY KF, McMurray JJV
    SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure.
    Eur J Heart Fail. 2020 Dec 6. doi: 10.1002/ejhf.2075.
    PubMed    


  718. ZELNIKER TA, Morrow DA, Mosenzon O, Goodrich EL, et al
    Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without SGLT2 inhibitor therapy in DECLARE-TIMI 58.
    Eur J Heart Fail. 2020 Dec 2. doi: 10.1002/ejhf.2073.
    PubMed     Abstract available



  719. Addendum to the article: 'Improving risk prediction in heart failure using machine learning' [Eur J Heart Fail 2020;22:139-147].
    Eur J Heart Fail. 2020;22:2399.
    PubMed    


  720. WANG N, Cao J, Lal S
    COVID-19: getting to the heart of the matter.
    Eur J Heart Fail. 2020;22:2216-2218.
    PubMed    


  721. TOMASONI D, Adamo M, Metra M
    December 2020 at a glance: focus on COVID-19, comorbidities and palliative care.
    Eur J Heart Fail. 2020;22:2173-2174.
    PubMed    


  722. LEBEK S, Tafelmeier M, Messmann R, Provaznik Z, et al
    Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.
    Eur J Heart Fail. 2020;22:2248-2257.
    PubMed     Abstract available


  723. BHATT AS, Vaduganathan M
    Discovery and care innovation amidst a pandemic.
    Eur J Heart Fail. 2020;22:2202-2204.
    PubMed    


  724. FARMAKIS D
    Is cardio-oncology a rapidly growing field of precision medicine?
    Eur J Heart Fail. 2020;22:2310-2313.
    PubMed    


  725. KONSTAM MA
    Ventricular remodelling: an equal-opportunity prognosticator.
    Eur J Heart Fail. 2020;22:2269-2271.
    PubMed    


    November 2020
  726. PACKER M, Butler J, Filippatos G, Zannad F, et al
    Design of a Prospective Patient-Level Pooled Analysis of Two Parallel Trials of Empagliflozin in Patients With Established Heart Failure.
    Eur J Heart Fail. 2020 Nov 30. doi: 10.1002/ejhf.2065.
    PubMed     Abstract available


  727. GREENBERG B, Janvanishstaporn S, Feng S
    Reply to Letter: Worsening Renal Function After Diuresis Among Heart Failure Patients with Preserved Ejection Fraction --- A Dilemma to Heart Failure Management.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2067.
    PubMed    


  728. ANKER SD, Butler J, Filippatos G, Khan MS, et al
    Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2064.
    PubMed     Abstract available


  729. BOORSMA EM, Beusekamp JC, Ter Maaten JM, Figarska SM, et al
    Effects of Empagliflozin on Renal Sodium and Glucose Handling in Patients with Acute Heart Failure.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2066.
    PubMed     Abstract available


  730. ANKER MS, Sanz AP, Zamorano JL, Mehra MR, et al
    Advanced cancer is also a heart failure syndrome - an hypothesis.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2071.
    PubMed     Abstract available


  731. MADELAIRE C, Kristensen SL
    Patterns of unplanned readmissions after heart failure hospitalization: novel longitudinal perspectives from Australia and New Zealand.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2068.
    PubMed    


  732. D'AMARIO D, Borovac JA, Crea F
    Coronary microvascular dysfunction in heart failure with preserved ejection fraction: not the end but the end of the beginning.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2069.
    PubMed    


  733. HALLIDAY BP, Owen R, Gregson J, Vassiliou V, et al
    Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy - insights from TRED-HF.
    Eur J Heart Fail. 2020 Nov 22. doi: 10.1002/ejhf.2063.
    PubMed     Abstract available


  734. CANEPA M, Kapelios CJ, Lund LH
    Acknowledging the complex puzzle that links heart failure hospitalizations and outcomes.
    Eur J Heart Fail. 2020 Nov 22. doi: 10.1002/ejhf.2061.
    PubMed    


  735. DONAL E, Galli E, Paven E, Sade LE, et al
    Haemodynamic evaluation: a key tool for heart failure management.
    Eur J Heart Fail. 2020 Nov 20. doi: 10.1002/ejhf.2055.
    PubMed    


  736. BIEGUS J, Zymlinski R, Testani J, Marciniak D, et al
    Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high risk acute heart failure patients.
    Eur J Heart Fail. 2020 Nov 14. doi: 10.1002/ejhf.2053.
    PubMed     Abstract available


  737. TOMASONI D, Inciardi RM, Lombardi CM, Tedino C, et al
    Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2052.
    PubMed     Abstract available


  738. VERNOOY K, Brunner-La Rocca HP
    The importance of the electrocardiographic follow-up in heart failure.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2054.
    PubMed    


  739. DUSI V, Vitolo V, Frigerio L, Totaro R, et al
    The First-in-Man Case of Non-invasive Proton Radiotherapy to Treat Refractory Ventricular Tachycardia in Advanced Heart Failure.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2056.
    PubMed    


  740. STARWALT JL, Ho AF, Wang H
    Worsening Renal Function After Diuresis Among Heart Failure Patients with Preserved Ejection Fraction --- A Dilemma to Heart Failure Management.
    Eur J Heart Fail. 2020 Nov 8. doi: 10.1002/ejhf.2050.
    PubMed    


  741. KRESOJA KP, Rommel KP, Thiele H, Lurz P, et al
    Response to the letter regarding the article: Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2020 Nov 4. doi: 10.1002/ejhf.2048.
    PubMed    


  742. KONIG S, Hohenstein S, Meier-Hellmann A, Kuhlen R, et al
    In-hospital Care in Acute Heart Failure during the COVID-19 Pandemic: Insights from the German-wide Helios Hospital Network.
    Eur J Heart Fail. 2020 Nov 2. doi: 10.1002/ejhf.2044.
    PubMed     Abstract available


  743. FABRIS E, Sinagra G, Valgimigli M
    Antithrombotic therapy in heart failure and sinus rhythm: the ongoing search for a better match of patients to therapy.
    Eur J Heart Fail. 2020 Nov 1. doi: 10.1002/ejhf.2045.
    PubMed    


  744. VOLTERRANI M, Perrone V, Sangiorgi D, Giacomini E, et al
    Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study.
    Eur J Heart Fail. 2020;22:2049-2055.
    PubMed     Abstract available



  745. Corrigendum to 'Departments involved during the first episode of acute heart failure and analysis of emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort' [Eur J Heart Fail 2019;21:1231-1244].
    Eur J Heart Fail. 2020;22:2172.
    PubMed    


  746. JANKOWSKA EA, Tkaczyszyn M, Ponikowski P
    Myocardial iron content in non-ischaemic cardiomyopathy: how much is known?
    Eur J Heart Fail. 2020;22:2047-2048.
    PubMed    


  747. RICHARDS AM
    Beating the bushes for biomarkers.
    Eur J Heart Fail. 2020;22:2075-2077.
    PubMed    


  748. OKWUOSA TM, Keramida K, Filippatos G, Yancy CW, et al
    Cancer therapy and the heart; the necessity to calibrate risk.
    Eur J Heart Fail. 2020;22:1961-1965.
    PubMed    


  749. SEFEROVIC PM, Polovina M
    In search of a 'safety zone' for glycaemic control: association between glycosylated haemoglobin levels and outcomes in patients with type 2 diabetes and cardiovascular disease.
    Eur J Heart Fail. 2020;22:2035-2037.
    PubMed    


  750. KEHLER DS, Arora RC
    Frailty and the failing heart do not travel alone.
    Eur J Heart Fail. 2020;22:2120-2122.
    PubMed    


  751. COWIE MR
    DAPA-HF: does dapagliflozin provide 'bang for your buck' as a treatment for heart failure with reduced ejection fraction?
    Eur J Heart Fail. 2020;22:2157-2159.
    PubMed    


    October 2020
  752. KOUDSTAAL S, Den Ruijter HM, Peters SAE
    Sex Differences and Heart Failure - A Story of Two Tales.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2041.
    PubMed    


  753. WAGNER J, Ambrosy AP
    Hospitalizations for Heart Failure and Mortality Risk During the Evolving Coronavirus Disease 2019 Pandemic - The Wave May Break but A Dangerous Undertow Persists.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2043.
    PubMed    


  754. AHMED F
    Letter regarding the article Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2037.
    PubMed    


  755. PELLICORI P, Platz E, Dauw J, Ter Maaten JM, et al
    Ultrasound imaging of congestion in heart failure - Examinations beyond the heart.
    Eur J Heart Fail. 2020 Oct 29. doi: 10.1002/ejhf.2032.
    PubMed     Abstract available


  756. WHITELAW S, Sullivan K, Eliya Y, Alruwayeh M, et al
    Trial characteristics associated with under-enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: A systematic review.
    Eur J Heart Fail. 2020 Oct 29. doi: 10.1002/ejhf.2034.
    PubMed     Abstract available


  757. KLOMPSTRA L, Kyriakou M, Lambrinou E, Piepoli MF, et al
    Measuring physical activity with activity monitors in patients with heart failure. From literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiol
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2035.
    PubMed     Abstract available


  758. SIERPINSKI R, Josiak K, Suchocki T, Wojtas-Polc K, et al
    High Soluble Transferrin Receptor in Patients With Heart Failure: a Measure of Iron Deficiency And a Strong Predictor of Mortality.
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2036.
    PubMed     Abstract available


  759. BEKFANI T, Fudim M, Cleland JGF, Jorbenadze A, et al
    A Current and Future Outlook on Upcoming Technologies in the Remote Monitoring of Patients with Heart Failure.
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2033.
    PubMed     Abstract available


  760. CULIC V, Velat I
    Spironolactone discontinuation in patients with heart failure: complex interactions with loop diuretics.
    Eur J Heart Fail. 2020 Oct 23. doi: 10.1002/ejhf.2031.
    PubMed    


  761. LABROSCIANO C, Horton D, Air T, Tavella R, et al
    Frequency, Trends and Institutional Variation in 30-Day All-Cause Mortality and Unplanned Readmissions Following Hospitalisation for Heart Failure in Australia and New Zealand.
    Eur J Heart Fail. 2020 Oct 23. doi: 10.1002/ejhf.2030.
    PubMed     Abstract available


  762. DE BOER RA, Hulot JS, Gabriele Tocchetti C, Aboumsallem JP, et al
    Common Mechanistic Pathways in Cancer and Heart Failure.
    Eur J Heart Fail. 2020 Oct 22. doi: 10.1002/ejhf.2029.
    PubMed     Abstract available


  763. SEFEROVIC PM, Fragasso G, Petrie M, Mullens W, et al
    Heart Failure Association of the European Society of Cardiology Update on Sodium Glucose Co-transporter-2 Inhibitors in Heart Failure (an update on the Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. The position
    Eur J Heart Fail. 2020 Oct 17. doi: 10.1002/ejhf.2026.
    PubMed     Abstract available


  764. KOEHLER J, Stengel A, Hofmann T, Wegscheider K, et al
    Telemonitoring in patients with chronic heart failure and moderate depressed symptoms - results of the Telemedical Interventional Monitoring in Heart Failure (TIM-HF) study.
    Eur J Heart Fail. 2020 Oct 15. doi: 10.1002/ejhf.2025.
    PubMed     Abstract available


  765. KASSNER A, Oezpeker C, Gummert J, Zittermann A, et al
    Mechanical circulatory support does not reduce advanced myocardial fibrosis in patients with terminal heart failure.
    Eur J Heart Fail. 2020 Oct 10. doi: 10.1002/ejhf.2021.
    PubMed    


  766. SAED ALHAKAK A, Sengelov M, Jorgensen PG, Bruun NE, et al
    Left Ventricular Systolic Ejection Time is an Independent Predictor of All-Cause Mortality in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2020 Oct 9. doi: 10.1002/ejhf.2022.
    PubMed     Abstract available


  767. ABRAHAM WT, Psotka MA, Fiuzat M, Filippatos G, et al
    Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium (HF-ARC).
    Eur J Heart Fail. 2020 Oct 5. doi: 10.1002/ejhf.2018.
    PubMed     Abstract available


  768. PUDIL R, Mueller C, Celutkiene J, Henriksen PA, et al
    The role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and Cardio-Oncology Council of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Oct 2. doi: 10.1002/ejhf.2017.
    PubMed     Abstract available


  769. COATS AJS
    Pulmonary artery pressure monitoring, a reality for Europe?
    Eur J Heart Fail. 2020;22:1905-1906.
    PubMed    


  770. GUSTAFSSON F, Lund LH, Metra M
    If it ain't broken, don't fix it (but if it is, make sure you know): aortic valve interventions during left ventricular assist device implantation.
    Eur J Heart Fail. 2020;22:1888-1890.
    PubMed    


  771. PARIKH PB, Tsigkas G, Kalogeropoulos AP
    Transcatheter aortic valve replacement after heart failure hospitalization: too little, too late?
    Eur J Heart Fail. 2020;22:1875-1877.
    PubMed    


  772. ADAMO M, Metra M, Alfieri O
    Percutaneous valve repair of functional mitral regurgitation: aiming at optimal and durable results.
    Eur J Heart Fail. 2020;22:1849-1851.
    PubMed    


  773. GRIFFIN JM, Maurer MS
    Cardiac amyloidosis in severe aortic stenosis: we can find it but what should we do?
    Eur J Heart Fail. 2020;22:1863-1865.
    PubMed    


  774. SCHNEIDER M, Mascherbauer J
    Improvement in nutritional status - a determinant of successful transcatheter tricuspid valve repair?
    Eur J Heart Fail. 2020;22:1837-1839.
    PubMed    


    September 2020
  775. TEERLINK JR, Diaz R, Felker GM, McMurray JJV, et al
    Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction, GALACTIC-HF: Baseline Characteristics and Comparison with Contemporary Clinical Trials.
    Eur J Heart Fail. 2020 Sep 27. doi: 10.1002/ejhf.2015.
    PubMed     Abstract available


  776. AHMAD A, Corban MT, Toya T, Verbrugge FH, et al
    Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2020 Sep 19. doi: 10.1002/ejhf.2010.
    PubMed     Abstract available


  777. TOMASONI D, Adamo M, Metra M
    September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy.
    Eur J Heart Fail. 2020;22:1493-1494.
    PubMed    


  778. KALOGEROPOULOS AP, Simitsis P, Skopicki HA
    Secrets of spironolactone: continuing insights from TOPCAT Americas.
    Eur J Heart Fail. 2020;22:1625-1627.
    PubMed    


  779. RITCHIE R, Galougahi KK, Figtree GA
    Targeting longevity genes in the battle against diabetic heart disease - is there a gene delivery fountain of youth?
    Eur J Heart Fail. 2020;22:1582-1585.
    PubMed    


  780. BISTOLA V, Polyzogopoulou E, Parissis J
    A novel strategy for the management of lung congestion: targeting TRPV4 channel, the 'gate keeper' of pulmonary capillary permeability.
    Eur J Heart Fail. 2020;22:1646-1648.
    PubMed    


  781. ZIAEIAN B, Butler J, Fonarow GC
    With great power comes great... reliability.
    Eur J Heart Fail. 2020;22:1708-1710.
    PubMed    


    August 2020
  782. HOWLETT JG
    The time has finally come to prioritize drug initiation before dose titration for patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2020;22:1483-1485.
    PubMed    


  783. MONTGOMERY RA, Tang WHW
    A means to an end: the promise of tracking natriuresis with diuretic therapy.
    Eur J Heart Fail. 2020;22:1448-1450.
    PubMed    


    July 2020
  784. VADUGANATHAN M, Pareek M, Kristensen AMD, Biering-Sorensen T, et al
    Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy.
    Eur J Heart Fail. 2020 Jul 21. doi: 10.1002/ejhf.1971.
    PubMed     Abstract available


  785. EKSTROM K, Raisanen-Sokolowski A, Lehtonen J, Kupari M, et al
    Long-term outcome and its predictors in giant cell myocarditis. Letter regarding the article 'Long-term outcome and its predictors in giant cell myocarditis'.
    Eur J Heart Fail. 2020;22:1283-1284.
    PubMed    


  786. SEFEROVIC PM, Asanin M, Polovina M
    Practice makes perfect: improved long-term survival in non-ischaemic dilated cardiomyopathy with contemporary treatment.
    Eur J Heart Fail. 2020;22:1122-1124.
    PubMed    


  787. GORTER TM, van Veldhuisen DJ, Dickinson MG
    Right-sided cardiac disease: no longer the 'dark side of the heart'.
    Eur J Heart Fail. 2020;22:1226-1229.
    PubMed    


  788. INCIARDI RM, Rossi A
    Mitral regurgitation, edge-to-edge valve repair and the left atrium: one step beyond the left ventricle?
    Eur J Heart Fail. 2020;22:1211-1213.
    PubMed    


  789. SEFEROVIC PM, Polovina MM
    A new perspective of an old tool: an everlasting benefit of the electrocardiogram in dilated cardiomyopathy.
    Eur J Heart Fail. 2020;22:1108-1110.
    PubMed    


  790. MICHEL L, Rassaf T, Totzeck M
    Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis? Reply.
    Eur J Heart Fail. 2020;22:1285-1286.
    PubMed    


  791. AIMO A, Fabiani I, Emdin M
    Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis?. Letter regarding the article 'Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis.'
    Eur J Heart Fail. 2020;22:1284-1285.
    PubMed    


  792. TER MAATEN JM, Said F, Maass AH
    Factors predicting recovery of left ventricular dysfunction in non-ischaemic cardiomyopathy.
    Eur J Heart Fail. 2020;22:1171-1173.
    PubMed    


  793. ZWEERINK A, Allaart CP, Burri H
    Shifting diastolic filling from right to left in non-obstructive hypertrophic cardiomyopathy: exploring new indications for biventricular pacing.
    Eur J Heart Fail. 2020;22:1273-1275.
    PubMed    


    June 2020
  794. KLEIN P, Anker SD, Wechsler A, Kelle S, et al
    Left ventricular volume reduction and reshape - 'Re-STICHING' the field. Reply.
    Eur J Heart Fail. 2020;22:1053-1054.
    PubMed    


  795. FERREIRA JP
    Health-related quality of life scores: ending the minimum 5-point difference as the clinically meaningful threshold.
    Eur J Heart Fail. 2020;22:1006-1008.
    PubMed    


  796. BONIOS MJ, Kogerakis N, Adamopoulos SN
    Left ventricular volume reduction and reshape - 'Re-STICHING' the field. Letter regarding the article 'Less invasive ventricular reconstruction for ischaemic heart failure'.
    Eur J Heart Fail. 2020;22:1053.
    PubMed    


    May 2020
  797. HAWKINS NM, Osmanska J, Petrie MC
    Implantable cardioverter-defibrillators and survival - the fine line between efficacy concerns and ageism.
    Eur J Heart Fail. 2020;22:868-870.
    PubMed    


  798. BOLLI R, Kahlon A
    Time to end the war on cell therapy.
    Eur J Heart Fail. 2020;22:893-897.
    PubMed    


  799. FURTADO RHM, Bergmark B
    Ejection fraction versus B-type natriuretic peptide for revascularization strategy in left main disease: two sides of the same coin or a wooden nickel?
    Eur J Heart Fail. 2020;22:880-883.
    PubMed    


  800. CHATTERJEE NA, Levy WC
    Sudden cardiac death after myocardial infarction.
    Eur J Heart Fail. 2020;22:856-858.
    PubMed    


    April 2020
  801. DE LUCA L, Savonitto S
    Composite trends of cardiogenic shock complicating acute myocardial infarction.
    Eur J Heart Fail. 2020;22:673-675.
    PubMed    


    March 2020
  802. STEWART COATS AJ
    Validating the HFA-PEFF score - or how to define a disease?
    Eur J Heart Fail. 2020;22:428-431.
    PubMed    


  803. WESTIN O, Fosbol E, Gustafsson F
    Refining the role of carpal tunnel syndrome in cardiac amyloidosis.
    Eur J Heart Fail. 2020;22:516-518.
    PubMed    


  804. SHEN L, Jhund P, McMurray J
    Dyslipidaemia, a factor worthy of adjustment: reply.
    Eur J Heart Fail. 2020;22:564-565.
    PubMed    


  805. SKELIN M, Lucijanic M, Lucijanic J
    Dyslipidaemia, a factor worthy of adjustment.
    Eur J Heart Fail. 2020;22:564.
    PubMed    


    February 2020
  806. GRODIN JL, Rao A, Zaha VG
    Myocardial dysfunction in breast cancer survivors: 'you can observe a lot by just watching'.
    Eur J Heart Fail. 2020;22:347-349.
    PubMed    


  807. MAGLIOCCA A, Omland T, Latini R
    Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more.
    Eur J Heart Fail. 2020;22:300-302.
    PubMed    


  808. RAJU B, McCullough PA
    Circulating plasma dipeptidyl dipeptidase 3 and the prognosis of cardiogenic shock.
    Eur J Heart Fail. 2020;22:287-289.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: